WO2018161033A1 - Inhibiteurs ire1-alpha à petites molécules - Google Patents

Inhibiteurs ire1-alpha à petites molécules Download PDF

Info

Publication number
WO2018161033A1
WO2018161033A1 PCT/US2018/020763 US2018020763W WO2018161033A1 WO 2018161033 A1 WO2018161033 A1 WO 2018161033A1 US 2018020763 W US2018020763 W US 2018020763W WO 2018161033 A1 WO2018161033 A1 WO 2018161033A1
Authority
WO
WIPO (PCT)
Prior art keywords
ring
alkyl
compound
linkage
heterocyclyl
Prior art date
Application number
PCT/US2018/020763
Other languages
English (en)
Inventor
Laurie H. Glimcher
Juan Rodrigo Cubillos-Ruiz
Sarah Elizabeth BETTIGOLE
Joseph P. Vacca
Original Assignee
Wright, Adrian
Tarver, Gary
MAMJEE, Manoj
ALVAREZ, Silvia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wright, Adrian, Tarver, Gary, MAMJEE, Manoj, ALVAREZ, Silvia filed Critical Wright, Adrian
Publication of WO2018161033A1 publication Critical patent/WO2018161033A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/80—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Definitions

  • IRE1 ⁇ inhibitors Described herein are IRE1 ⁇ inhibitors, compositions containing such inhibitors, and methods of treatment that include administration of such compounds. Examples of such inhibitors are provided throughout the application.
  • XBP1 can promote tumor progression by confounding the development of protective antitumor immunity in the ovarian cancer tumor microenvironment. Without XBP1, tumor resident dendritic cells fail to accumulate intracellular lipids, which normally disrupt effective antigen cross-presentation. This pathological lipid accumulation is fundamentally driven by reactive oxygen species-mediated lipid peroxidation, which directly destabilizes protein-folding chaperones within the endoplasmic reticulum to induce a state of ER stress and XBP1 activation. Additionally, the inventors have found that IRE1 ⁇ -mediated XBP1 signaling is involved in myeloid cell production of immunosuppressive prostaglandins such as prostaglandin E2 (PGE2).
  • PGE2 prostaglandin E2
  • IRE1 ⁇ kinase inhibitors that exhibit immune-modulatory properties and/or allosterically block IRE1alpha endoribonuclease function.
  • the identified direct IRE1 ⁇ inhibitors have unique chemical structures, unique binding mechanisms, inhibitory activity, and off-target effects.
  • the A ring is a heterocyclyl or aryl
  • x is an integer of 0-2;
  • R 1 is independently amino, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, hydroxy, C 1 -C 4 hydroxyalkyl, arylsulfonyl, cyano, halogen, or trifluoromethyl;
  • the linkage 1 is a single bond, C1-C3 alkyl, C2-C3 alkenyl or C2-C3 alkynyl;
  • the B ring is a heterocyclyl or aryl
  • y is an integer of 0-1;
  • R 2 is independently amino, C1-C4 alkyl, halogen or trifluoromethyl
  • linkage 2 is amino, urea, amido, alkylamido, alkenylamido, amidoalkyl, amidoalkenyl, alkylurea, or alkenylurea;
  • the C ring is a heterocyclyl or aryl
  • z is an integer of 0-2;
  • R 3 is independently amino, C1-C4 alkyl, C1-C4 alkoxy, hydroxy, C1-C4 hydroxyalkyl, cyano, halogen, trifluoromethyl, difluoromethyl, monofluoroalkyl, benzyl, dialkylaminosulfonyl, alkylsulfonyl, boronic ester, boronic acid, dialkylphosphine, C1-C4 alkylcarboxyl, dialkylamido, cycloalkylalkyl, or heterocyclylalkyl;
  • Another aspect is a compound of Formula II,
  • the A ring is a heterocyclyl or aryl
  • R 1 is independently amino, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, hydroxy, C 1 -C 4 hydroxyalkyl, arylsulfonyl, cyano, halogen, or trifluoromethyl;
  • the linkage 1 is a single bond, C1-C3 alkyl, C2-C3 alkenyl or C2-C3 alkynyl;
  • the B ring is a heterocyclyl or aryl
  • y is an integer of 0-1;
  • R 2 is independently amino, C1-C4 alkyl, halogen or trifluoromethyl
  • linkage 2 is amino, urea, amido, alkylamido, alkenylamido, amidoalkyl, amidoalkenyl, alkylurea, or alkenylurea;
  • G is dialkylamino or H
  • the A ring is a heterocyclyl or aryl
  • x is an integer of 0-2;
  • R 1 is independently amino, C1-C4 alkyl, C1-C4 alkoxy, hydroxy, C1-C4 hydroxyalkyl, arylsulfonyl, cyano, halogen, trifluoromethyl or a group having the structure
  • D ring is a heterocyclyl
  • v is an integer of 0-2;
  • R D is amino, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, hydroxy, C 1 -C 4 hydroxyalkyl, arylsulfonyl, cyano, halogen, or trifluoromethyl;
  • linkage D is a single bond, amino or C1-C3 alkyl
  • the B 1 ring is a heterocyclyl or aryl
  • y is an integer of 0-1;
  • R 5 is independently amino, C1-C3 alkyl, halogen or trifluoromethyl
  • the B 2 ring is phenyl, pyridinyl, naphthyl or a bicyclic heterocyclyl
  • z is an integer of 0-1;
  • R 6 is independently amino, C1-C4 alkyl, halogen or trifluoromethyl
  • the C ring is a heterocyclyl
  • R 3 is independently C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 hydroxyalkyl, hydroxy, aryl, benzyl, benzaldehyde, halogen, cyano, amino, heterocyclyl, heterocyclylalkyl, cycloalkyl, cycloalkylalkyl, trifluoromethyl, difluoromethyl, monofluoroalkyl, dialkylaminosulfonyl, alkylsulfonyl, dialkylphosphine, C1-C4 alkylcarboxyl, dialkylamido, or dialkylamino;
  • linkage A is a single bond, is a C1-C5 alkyl, alkenyl, alkynyl, alkylamido, acyl, or oxo(carbonyl)alkyl;
  • linkage B is alkylamido, alkenylamido, amidoalkyl, amidoalkenyl, urea, alkylurea, or alkenylurea;
  • the linkage C is CH or (CH 2 ) n , where n is an integer of 0-3, and when n is 0, the linkage between the B 2 ring and the C ring is a single bond;
  • Another aspect is compound selected from any of the compounds in the Examples, or a pharmaceutically acceptable salt thereof.
  • compositions that includes a carrier and any of the compounds of formula I, II or III, pharmaceutically acceptable salts thereof, or any combination of such compounds.
  • compositions that includes a carrier and any of the compounds in the Examples, pharmaceutically acceptable salts thereof, or any combination thereof.
  • Another aspect is a method that includes administering one or more of such compositions to a mammal.
  • the mammal can be in need of administration of the composition.
  • a mammal can, for example, have cancer, a neurodegenerative disease, inflammation, a metabolic disorder, liver dysfunction, brain ischemia, heart ischemia, or an autoimmune disease such as systemic lupus erythematosus.
  • the mammal has triple negative breast cancer or ovarian cancer.
  • compositions and methods described herein can include one or more agents such as vitamin E, an antioxidant, and/or hydralazine.
  • agents can sequester lipid peroxidation byproducts, and can be effective treatments for controlling ER stress responses and sustained IRE1 ⁇ /XBP1 signaling in tumor-associated dendritic cells exposed, for example, to ovarian cancer-derived ascites.
  • FIG.1A is the structure of vitamin E (VitE).
  • FIG. 1B is the structure of hydralazine (Hlz), a representative member of lipid peroxidation-sequestering hydrazines.
  • FIG. 1C is RT-qPCR analyses of markers of ER stress after culturing purified tumor-resident DCs in the absence (grey bars) or presence (green bars) of 25% cell-free ovarian cancer ascites supernatants for 18 hours. Data are normalized to Actb expression in each sample.
  • FIG.1D is flow cytometry analysis of lipid accumulation in mouse bone marrow-derived dendritic cells exposed to the indicated treatments, measured by BODIPY 493/503 staining intensity. Both raw data and quantified geometric mean fluorescence intensity (MFI) are shown,
  • FIG. 2A is a cartoon of a cleavable RNA probe and IRE1 ⁇ -dependent hairpin cleavage site.
  • the quenching dye is released, fluorescence is emitted.
  • FIG.2B is a cartoon of a point mutation (G ⁇ C) in the hairpin that abrogates IRE1 ⁇ activity against RNA probe, controlling for contamination by non-specific RNAses.
  • G ⁇ C point mutation
  • FIG. 3 is the structure of an IRE1 ⁇ inhibitor identified by computational screening and confirmed by human IRE1 ⁇ FRET assay (commercially available from InterBioScreen).
  • IRE1 ⁇ is a type I transmembrane protein with dual enzymatic activities, including an N-terminal domain that projects into the luminal side of the endoplasmic reticulum (IRE1-LD) and a serine/threonine kinase domain plus a C-terminal ribonuclease (RNase) domain located on the cytosolic side of the protein.
  • IRE1-LD endoplasmic reticulum
  • RNase C-terminal ribonuclease
  • the compounds include any of those described herein, including compounds shown in the Examples. In some instances, the compounds are embraced by Formula I:
  • the A ring is a heterocyclyl or aryl
  • R 1 is independently amino, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, hydroxy, C 1 -C 4 hydroxyalkyl, arylsulfonyl, cyano, halogen, or trifluoromethyl;
  • the linkage 1 is a single bond, C1-C3 alkyl, C2-C3 alkenyl or C2-C3 alkynyl;
  • the B ring is a heterocyclyl or aryl
  • y is an integer of 0-1;
  • R 2 is independently amino, C1-C4 alkyl, halogen or trifluoromethyl
  • linkage 2 is amino, urea, amido, alkylamido, alkenylamido, amidoalkyl, amidoalkenyl, alkylurea, or alkenylurea;
  • the C ring is a heterocyclyl or aryl
  • z is an integer of 0-2;
  • R 3 is independently amino, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, hydroxy, C 1 -C 4 hydroxyalkyl, cyano, halogen, trifluoromethyl, difluoromethyl, monofluoroalkyl, benzyl, dialkylaminosulfonyl, alkylsulfonyl, boronic ester, boronic acid, dialkylphosphine, C 1 -C 4 alkylcarboxyl, dialkylamido, cycloalkylalkyl, or heterocyclylalkyl;
  • linkage 1 in compounds of the Formula I can be a single bond.
  • the linkage 1 in compounds of the Formula I can be C1-C3 alkyl, C 2 -C 3 alkenyl or C 2 -C 3 alkynyl; and the linkage 2 is a urea, alkylurea, or alkenylurea.
  • the A ring is a heterocyclyl or aryl
  • x is an integer of 0-2;
  • R 1 is independently amino, C1-C4 alkyl, C1-C4 alkoxy, hydroxy, C1-C4 hydroxyalkyl, arylsulfonyl, cyano, halogen, or trifluoromethyl;
  • the linkage 1 is a single bond, C1-C3 alkyl, C2-C3 alkenyl or C2-C3 alkynyl;
  • the B ring is a heterocyclyl or aryl
  • y is an integer of 0-1;
  • R 2 is independently amino, C1-C4 alkyl, halogen or trifluoromethyl
  • linkage 2 is amino, urea, amido, alkylamido, alkenylamido, amidoalkyl, amidoalkenyl, alkylurea, or alkenylurea;
  • G is dialkylamino or H,
  • the A ring is a heterocyclyl or aryl
  • x is an integer of 0-2;
  • R 1 is independently amino, C1-C4 alkyl, C1-C4 alkoxy, hydroxy, C1-C4 hydroxyalkyl, arylsulfonyl, cyano, halogen, trifluoromethyl or a group having the structure
  • v is an integer of 0-2;
  • R D is amino, C1-C4 alkyl, C1-C4 alkoxy, hydroxy, C1-C4 hydroxyalkyl, arylsulfonyl, cyano, halogen, or trifluoromethyl;
  • linkage D is a single bond, amino or C 1 -C 3 alkyl
  • the B 1 ring is a heterocyclyl or aryl
  • y is an integer of 0-1;
  • R 5 is independently amino, C 1 -C 3 alkyl, halogen or trifluoromethyl
  • the B 2 ring is phenyl, pyridinyl, naphthyl or a bicyclic heterocyclyl
  • z is an integer of 0-1;
  • R 6 is independently amino, C 1 -C 4 alkyl, halogen or trifluoromethyl
  • the C ring is a heterocyclyl ring
  • w is an integer of 0-2;
  • R 3 is independently C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 hydroxyalkyl, hydroxy, aryl, benzyl, benzaldehyde, halogen, cyano, amino, heterocyclyl, heterocyclylalkyl, cycloalkyl, cycloalkylalkyl, trifluoromethyl, difluoromethyl, monofluoroalkyl, dialkylaminosulfonyl, alkylsulfonyl, dialkylphosphine, C1-C4 alkylcarboxyl, dialkylamido, or dialkylamino;
  • the linkage A is a single bond, is a C1-C5 alkyl, alkenyl, alkynyl, alkylamido, acyl, or oxo(carbonyl)alkyl;
  • the linkage B is alkylamido, alkenylamido, amidoalkyl, amidoalkenyl, urea, alkylurea, or alkenylurea;
  • the linkage C is CH or (CH2)n, where n is an integer of 0-3, and when n is 0, the linkage between the B 2 ring and the C ring is a single bond;
  • x can be 1-2; and at least one of R 4
  • w can be 1-2; and at least one of R 8 can be heterocyclyl, heterocyclylalkyl, cycloalkyl or cycloalkylalkyl.
  • linkage A is alkynyl and linkage B is urea, then A can be aryl.
  • At least one of X, Y Z and W can be other than 0.
  • the A ring can be heteroaromatic.
  • the A ring can be indazole, imadazopyridine, imadazopyrazine, imadazopyridazine, pyrrolopyridine, hexahydrothienopyrimidine, imidazole, pyrazole, pyrazine, pyridine, pyrimidine, phenylpyrimidinamine, quinolinyl, isoquinolinyl, tetrahydroquinolinyl or quinazolinyl.
  • the A ring can be a single, non- fused ring.
  • the A ring can be a fusion of two rings.
  • the A ring is phenyl.
  • a rings include indazole, imadazopyridine, imadazopyrazine, imadazopyridazine, pyrrolopyridine, hexahydrothienopyrimidine, imidazole, pyrazole, pyrazine, pyridine, pyrimidine, and phenylpyrimidinamine.
  • the A ring can be:
  • the A ring can be: [0036]
  • the A ring can be: [0037]
  • the A ring can be:
  • the A ring can be: .
  • the R1 substituents on the A ring can, for example, be selected from amino and C 1 -C 4 alkyl.
  • the R 1 substituents on the A ring can, for example, be selected from amino and C1-C3 alkyl.
  • the R1 substituents on the A ring can be selected from—NH2 and—CH3.
  • x can be 0.
  • x can be 1.
  • x can be 0 when the A ring is a fusion of two rings.
  • x can be 1 or 2 when the A ring is a single, nonfused ring.
  • R 4 on the A ring can be independently amino, C1-C4 alkyl, C1-C4 alkoxy, hydroxy, C 1 -C 4 hydroxyalkyl, arylsulfonyl, cyano, halogen, trifluoromethyl
  • the D ring is a heterocyclyl; v is an integer of 0-2; R D is amino, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, hydroxy, C1-C4 hydroxyalkyl, arylsulfonyl, cyano, halogen, or trifluoromethyl ; and the linkage D is a single bond, amino or C 1 -C 3 alkyl.
  • the linkage d can be a single bond.
  • the linkage d can be a methylene.
  • R 4 on the A ring can be independently amino, C1-C4 alkyl, hydroxy or halogen. Or R 4 can be independently amino or substituted C 1 -C 4 alkyl. Or R 4 can be independently amino or unsubstituted C 1 -C 4 alkyl. R 4 can be amino. Or R 4 can be unsubstituted C 1 -C 4 alkyl.
  • the B ring can be a single, non-fused ring.
  • the B ring can be a fusion of two rings.
  • the B ring can be selected from any of the following:
  • the B ring can be: [0044] The B ring can be: [0045] The B ring can be:
  • the B ring can, for example, be phenyl, naphthalene, tetrahydronaphthalene, or a bicyclic heterocycle.
  • Such B ring bicyclic heterocycle can be a spirodecane where one or two of the ring carbons is nitrogen rather than carbon.
  • a B ring bicyclic heterocycle can have any of the following structures:
  • R 2 on the B ring can be independently amino, C1-C4 alkyl, halogen or trifluoromethyl. Or R 2 can be independently amino, C 1 -C 4 alkyl, or trifluoromethyl. Or R 2 can be independently C1-C4 alkyl or trifluoromethyl. Or R 2 can be unsubstituted C1-C4 alkyl. Or R 2 can be substituted C1-C4 alkyl.
  • the R 2 substituents on the B ring can be optionally substituted C 1 - C 4 alkyl. Or the R 2 substituents on the B ring can be optionally substituted C 1 -C 3 alkyl. Or the R 2 substituents on the B ring can be methyl. Or the R 2 substituents on the B ring can be optionally substituted linear C 1 -C 4 alkyl. Or the R 2 substituents on the B ring can be unsubstituted. Or the R 2 substituents on the B 1 ring can be amino. Or the R 2 substituents on the B ring can be trifluoromethyl. Or the R 2 substituents on the B ring can be halogen.
  • the B 1 ring can be heteroaromatic.
  • the B 1 ring can be indazole, imadazopyridine, imadazopyrazine, imadazopyridazine, pyrrolopyridine, hexahydrothienopyrimidine, imidazole, pyrazole, pyrazine, pyridine, pyrimidine, phenylpyrimidinamine, quinolinyl, isoquinolinyl, tetrahydroquinolinyl or quinazolinyl.
  • the B 1 ring can be pyrazolyl, imidazolyl, or triazolyl.
  • the B 1 ring can be a single, non-fused ring.
  • the B 1 ring can be a fusion of two rings. Or the B 1 ring can be phenyl.
  • the B 1 ring can be a single, non-fused ring. Alternatively, the B 1 ring can be a fusion of two rings.
  • the B 1 ring can be selected from any of the following: [0051] [0052] The B 1 ring can be: [0053] The B 1 ring can be: [0054] The B 1 ring can be:
  • the B 1 ring can, for example, be phenyl, naphthalene, tetrahydronaphthalene, or a bicyclic heterocycle.
  • Such B 1 ring bicyclic heterocycle can be a spirodecane where one or two of the ring carbons is nitrogen rather than carbon.
  • a B 1 ring bicyclic heterocycle can have any of the following structures:
  • R 5 on the B 1 ring can be independently amino, C 1 -C 4 alkyl, halogen or trifluoromethyl. Or R 5 can be independently amino, C1-C4 alkyl, or trifluoromethyl. Or R 5 can be independently C1-C4 alkyl or trifluoromethyl. Or R 5 can be unsubstituted C 1 -C 4 alkyl. Or R 5 can be substituted C 1 -C 4 alkyl.
  • R 5 substituents on the B 1 ring can optionally be substituted C1-C4 alkyl. Or R 5 substituents on the B 1 ring can optionally be substituted C1-C3 alkyl. Or R 5 substituents on the B 1 ring can be methyl. R 5 substituents on the B 1 ring can optionally be substituted linear C1-C4 alkyl. R 5 substituents on the B 1 ring can be unsubstituted. R 5 substituents on the B 1 ring can be amino. R 5 substituents on the B 1 ring can be trifluoromethyl. R 5 substituents on the B 1 ring can be halogen.
  • B 2 can be a phenyl, pyridinyl, naphthyl or a bicyclic heterocyclyl.
  • the B 2 ring can be a phenyl group. Or the B 2 ring can be a pyridinyl group.
  • the B 2 ring can be a benzimidazole group.
  • the B 2 ring can be a naphthylene group.
  • the R 6 substituent on the B 2 ring can be CF3.
  • the B 2 ring can be pyridinyl.
  • the B 2 ring can be napthyl.
  • the B 2 ring can be bicyclic heterocyclyl.
  • R 6 on the B 2 ring can be independently amino, C1-C4 alkyl, halogen or trifluoromethyl.
  • R 6 can be independently amino, C1-C4 alkyl, or trifluoromethyl.
  • R 6 can be independently C 1 -C 4 alkyl or trifluoromethyl.
  • R 6 can be unsubstituted C1-C4 alkyl.
  • R 6 can be substituted C1-C4 alkyl.
  • R 6 substituents on the B 2 ring can be optionally substituted C1-C4 alkyl.
  • R 6 substituents on the B 2 ring can be optionally substituted C 1 -C 3 alkyl.
  • R 6 substituents on the B 2 ring can be methyl.
  • R 6 substituents on the B 2 ring can be optionally substituted linear C1-C4 alkyl.
  • R 6 substituents on the B 2 ring can be unsubstituted.
  • R 6 substituents on the B 2 ring can be amino.
  • R 6 substituents on the B 2 ring can be trifluoromethyl.
  • R 6 substituents on the B 2 ring can be halogen.
  • R 6 on the B 2 ring can be independently amino, C1-C4 alkyl, halogen or trifluoromethyl.
  • R 6 can be independently amino, C 1 -C 4 alkyl, or trifluoromethyl.
  • R 6 can be independently C1-C4 alkyl or trifluoromethyl.
  • R 6 can be unsubstituted C1-C4 alkyl.
  • R 6 can be substituted C1-C4 alkyl.
  • Linkage 1 can be methylene or acetylene.
  • Linkage 2 can be .
  • Linkage 1 can, for example, be selected from:
  • Linkage 1 can also be amino, amido, alkylamido, alkenylamido, amidoalkyl, or amidoalkenyl.
  • Linkage 1 can also be acylamido, acylamido, acylamidoalkyl, or acylamidoalkenyl.
  • Linkage 1 can also be amidoalkylamido, amidoalkenlamido, hydrazinyl, hydrazidyl, alkylhydrazinyl, alkylhydrazidyl, N- acylhydrazide, N-acylhydrazidyl, hydrazodicarbonyl, oxalamidyl, N-alkyl- oxalamidyl, acylurea, or dialkyldiamido, each of which may be optionally substituted.
  • Linkage 1 can contain at least one urea, amido, amino, alkyl, alkenyl, hydrazinyl, hydrazidyl, carbonyl, ester, and ether units, any of which may be optionally substituted.
  • Linkage 1 can contain at least two of urea, amido, amino, alkyl, alkenyl, hydrazinyl, hydrazidyl, carbonyl, ester, and ether units, any of which may be optionally substituted.
  • Linkage 1 can contain at least three of urea, amido, amino, alkyl, alkenyl, hydrazinyl, hydrazidyl, carbonyl, ester, and ether units, any of which may be optionally substituted.
  • Linkage 1 can contain at least four of urea, amido, amino, alkyl, alkenyl, hydrazinyl, hydrazidyl, carbonyl, ester, and ether units, any of which may be optionally substituted. Linkage 1 can also be a carbonyl. Linkage 1 can also be a alkoxy, alkylthio, sulfone or a thio.
  • Linkage 2 can be alkylamido, alkenylamido, amidoalkyl, or amidoalkenyl. Linkage 2 can be alkenylamido or amidoalkenyl.
  • the linkage 2 group can, for example, be selected from any of the following:
  • Linkage 2 can also be amino, amido, alkylamido, alkenylamido, amidoalkyl, or amidoalkenyl.
  • Linkage 2 can also be acylamido, acylamido, acylamidoalkyl, or acylamidoalkenyl.
  • Linkage 2 can also be amidoalkylamido, amidoalkenlamido, hydrazinyl, hydrazidyl, alkylhydrazinyl, alkylhydrazidyl, N- acylhydrazide, N-acylhydrazidyl, hydrazodicarbonyl, oxalamidyl, N-alkyl- oxalamidyl, acylurea, or dialkyldiamido, each of which may be optionally substituted.
  • Linkage 2 can contain at least one urea, amido, amino, alkyl, alkenyl, hydrazinyl, hydrazidyl, carbonyl, ester, and ether units, any of which may be optionally substituted.
  • Linkage 2 can contain at least two of urea, amido, amino, alkyl, alkenyl, hydrazinyl, hydrazidyl, carbonyl, ester, and ether units, any of which may be optionally substituted.
  • Linkage 2 can contain at least three of urea, amido, amino, alkyl, alkenyl, hydrazinyl, hydrazidyl, carbonyl, ester, and ether units, any of which may be optionally substituted.
  • Linkage 2 can contain at least four of urea, amido, amino, alkyl, alkenyl, hydrazinyl, hydrazidyl, carbonyl, ester, and ether units, any of which may be optionally substituted.
  • Linkage 2 can be a bond.
  • Linkage 2 can also be a carbonyl.
  • Linkage 2 can also be a alkylthio, sulfone or a thio.
  • Linkage A can be a single bond.
  • Linkage A can be methylene or acetylene.
  • Linkage A group can, for example, be selected from any of the following:
  • the linkage B group can, for example, be selected from any of the following:
  • linkage A is alkynyl and linkage B is urea
  • A can be aryl.
  • Linkage A can be other than alkynyl.
  • Linkage B can be other than urea.
  • Linkage B can be linkage B can be
  • Linkage B can be alkylamido, alkenylamido, amidoalkyl, or amidoalkenyl. Linkage B can be alkenylamido or amidoalkenyl.
  • Linkage C can be methylene
  • Linkage C can be a -CH- unit linked to ring C via a double bond.
  • the C ring can be heteroaromatic.
  • the C ring can be indazole, imadazopyridine, imadazopyrazine, imadazopyridazine, pyrrolopyridine, hexahydrothienopyrimidine, imidazole, pyrazole, pyrazine, pyridine, pyrimidine, phenylpyrimidinamine, quinolinyl, isoquinolinyl, tetrahydroquinolinyl or quinazolinyl.
  • the C ring can be pyrazolyl, imidazolyl, or triazolyl.
  • the C ring can be a single, non-fused ring.
  • the C ring can be a fusion of two rings.
  • the C ring can be phenyl.
  • the C ring can be a heterocyclyl ring containing at least one N atom.
  • the C ring can be piperidinyl, piperazinyl, or morpholinyl.
  • the C ring can be a phenyl group. Or the C ring can be a pyridinyl group.
  • the R 3 substituent on the C phenyl ring can be CF 3 .
  • the C ring can be a heterocyclyl or aryl ring.
  • the C ring can be a heterocyclyl ring.
  • the C ring can, for example, be selected from the following: , , , , , o .
  • the C ring can be a substituted heterocycle.
  • the C ring can be .
  • the C ring can be
  • R 3 substituents on the C ring can be selected from CH3, CH 3 CHCH 3 , CH 3 CH(CH 2 )CH 3 , and CH 3 CH 2 CH 3 OH.
  • the R 3 substituents on the C ring can be independently amino, C1- C4 alkyl, C1-C4 alkoxy, hydroxy, C1-C4 hydroxyalkyl, cyano, halogen, trifluoromethyl, difluoromethyl, monofluoroalkyl, benzyl, dialkylaminosulfonyl, alkylsulfonyl, boronic ester, boronic acid, dialkylphosphine, C1-C4 alkylcarboxyl, dialkylamido, cycloalkyl, cycloalkylalkyl, heterocyclyl or heterocyclylalkyl.
  • R 3 on the C ring can be independently C 1 -C 4 alkyl, C 1 -C 4 alkoxy, hydroxy, aryl, or benzyl.
  • R 3 can be substituted C1-C4 alkyl.
  • R 3 can be unsubstituted C1-C4 alkyl.
  • R 3 on the C ring can be non-aromatic heterocyclyl and aromatic heterocyclyl.
  • the R 3 substituents on the C ring can optionally be substituted C 1 -C 4 alkyl.
  • the R 3 substituents on the C ring can be selected from CH3, CH3CHCH3, CH3CH(CH2)CH3, and CH3CH2CH3OH.
  • R 3 can be CH3.
  • R 3 can optionally be substituted C 1 -C 4 alkoxy.
  • R 3 can be (optionally substituted C 1 -C 4 alkylene)-OH.
  • R 3 can be (optionally substituted C1alkylene)-OH.
  • R 3 can be (optionally substituted C2alkylene)-OH.
  • R 3 can be (optionally substituted C3alkylene)-OH.
  • R 3 can be (optionally substituted C 4 alkylene)-OH.
  • R 3 can be hydroxyl.
  • R 3 can be optionally substituted aryl.
  • R 3 can be phenyl.
  • R 3 can be optionally substituted benzyl.
  • R 3 can also be nitro, arylsulfonamido, amido, alkenyl, alkynyl, alkylsulfonyl, heterocycylcarbonyl, cycloalkylcarbonyl, trifluoromethoxy, alkylthio, and acetamido.
  • the D ring can be heteroaromatic.
  • the D ring can be indazole, imadazopyridine, imadazopyrazine, imadazopyridazine, pyrrolopyridine, hexahydrothienopyrimidine, imidazole, pyrazole, pyrazine, pyridine, pyrimidine, phenylpyrimidinamine, quinolinyl, isoquinolinyl, tetrahydroquinolinyl or quinazolinyl.
  • the D ring can be a single, non-fused ring.
  • the D ring can be a fusion of two rings.
  • D rings examples include indazole, imadazopyridine, imadazopyrazine, imadazopyridazine, pyrrolopyridine, hexahydrothienopyrimidine, imidazole, pyrazole, pyrazine, pyridine, pyrimidine, and phenylpyrimidinamine.
  • the D ring can be: [0089]
  • the D ring can be: [0091] The D ring can be: [0092] The D ring can be:
  • the R D substituents on the D ring can, for example, be selected from amino and C 1 -C 4 alkyl.
  • the R D substituents on the D ring can, for example, be selected from amino and C1-C3 alkyl.
  • the R D substituents on the D ring are selected from—NH2 and—CH3.
  • v can be 0 or v can be 1.
  • v can be 0 when the A ring is a fusion of two rings.
  • v can be 2 when the D ring is a single, nonfused ring.
  • x can be 0. Or x can be 1. Or x can be 2. y can be 0. Or y can be 1. z can be 0. z can be 1. z can be 2. v can be 0. v can be 1. v can be 2. w can be 0. w can be 1. w can be 2.
  • the C ring can be phenyl, a heterocycle indene, a dihydroindene, or benzodioxole.
  • the B 2 ring can be phenyl, a heterocycle indene, a dihydroindene, or benzodioxole.
  • the compounds can be the compounds as shown in Table 1 and Table 2.
  • “substituted” and“substituent” refers to an organic group as defined herein in which one or more bonds to a hydrogen atom contained therein are replaced by one or more bonds to a non-hydrogen atom such as, but not limited to, a halogen (i.e.,“halo” selected from F, Cl, Br, and I); an oxygen atom in groups such as hydroxyl groups, alkoxy groups, aryloxy groups, aralkyloxy groups, oxo(carbonyl) groups, carboxyl groups including carboxylic acids, carboxylates, and carboyxlate esters; a sulfur atom in groups such as thiol groups, alkyl and aryl sulfide groups, sulfoxide groups, sulfone groups, sulfonyl groups, and sulfonamide groups; a nitrogen atom in groups such as amines, hydroxylamines, nitriles, nitro groups, N-
  • Non-limiting examples of substituents that can be bonded to a substituted carbon (or other) atom include F, Cl, Br, I, OR ⁇ , OC(O)N(R ⁇ ) 2 , CN, CF 3 , OCF 3 , R ⁇ , O, S, C(O), S (O), methylenedioxy, ethylenedioxy, N(R ⁇ ) 2 SR ⁇ , SOR ⁇ , SO 2 R ⁇ , SO 1 N(R ⁇ ) 2 , SO 3 R ⁇ , C(O)R ⁇ , C(O)C(O)R ⁇ , C(O)CH2C(O)R ⁇ , C(S)R ⁇ , C(O)OR ⁇ , OC(O)R ⁇ , C(O)N(R ⁇ )2, OC(O)N(R ⁇ ) 2 , C(S)N(R ⁇ ) 2 , (CH 2 ) 0-2 NHC(O)R ⁇ , (CH 2 ) 0-2 N(R ⁇ )N(R ⁇ ) 2 , N(R ⁇ )
  • the substituents can be selected from amino, C1-C3 alkyl, ether, alkoxy, oxy, CF 3 , and cyano C 1 -C 3 alkoxy, benzyl, and benzaldehyde.
  • the ether and alkoxy groups can have 1-6 carbon atoms.
  • Substituted alkyl, alkenyl, alkynyl, cycloalkyl, and cycloalkenyl groups as well as other substituted groups also include groups in which one or more bonds to a hydrogen atom are replaced by one or more bonds, including double or triple bonds, to a carbon atom, or to a heteroatom such as, but not limited to, oxygen in carbonyl (oxo), carboxyl, ester, amide, imide, urethane, and urea groups; and nitrogen in imines, hydroxyimines, oximes, hydrazones, amidines, guanidines, and nitriles.
  • Substituted ring groups such as substituted aryl, heterocyclyl and heteroaryl groups also include rings and fused ring systems in which a bond to a hydrogen atom is replaced with a bond to a carbon atom. Therefore, substituted aryl, heterocyclyl and heteroaryl groups can also be substituted with alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, and alkynyl groups as defined herein, which can themselves be further substituted.
  • heteroatoms refers to non-carbon and non-hydrogen atoms, capable of forming covalent bonds with carbon, and is not otherwise limited. Typical heteroatoms are N, O, and S.
  • sulfur (S) When sulfur (S) is referred to, it is understood that the sulfur can be in any of the oxidation states in which it is found, thus including sulfoxides (R—S(O)—R ⁇ ) and sulfones (R— S(O)2—R ⁇ ), unless the oxidation state is specified; thus, the term“sulfone” encompasses only the sulfone form of sulfur; the term“sulfide” encompasses only the sulfide (R—S—R ⁇ ) form of sulfur.
  • phrases such as“heteroatoms selected from the group consisting of O, NH, NR ⁇ , and S,” or“[variable] is O, S.” are used, they are understood to encompass all of the sulfide, sulfoxide and sulfone oxidation states of sulfur.
  • Alkyl groups include straight chain and branched alkyl groups and cycloalkyl groups having from 1 to about 20 carbon atoms, and typically from 1 to 12 carbons or from 1 to 8 carbon atoms.
  • straight chain alkyl groups include those with from 1 to 8 carbon atoms such as methyl, ethyl, n-propyl, n- butyl, n-pentyl, n-hexyl, n-heptyl, and n-octyl groups.
  • branched alkyl groups include, but are not limited to, isopropyl, isobutyl, sec-butyl, t-butyl, neopentyl, isopentyl, and 2,2-dimethylpropyl groups.
  • Representative substituted alkyl groups can be substituted one or more times with any of the groups listed above, for example, amino, hydroxy, cyano, carboxy, nitro, thio, alkoxy, and halogen groups.
  • An“alkylene” group refers to a divalent alkyl radical. Any of the above mentioned monovalent alkyl groups may be an alkylene by abstraction of a second hydrogen atom from the alkyl.
  • An alkylene can be a C1-C6alkylene.
  • An alkylene can be a C1-C3alkylene. Examples of alkylene groups include, but are not limited to,—CH 2 —,—CH 2 CH 2 —,—CH 2 CH 2 CH 2 —,—CH 2 CH 2 CH 2 CH 2 —, and the like.
  • Cycloalkyl groups are alkyl groups forming a ring structure, which can be substituted or unsubstituted.
  • Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups.
  • the cycloalkyl group can have 3 to 8 ring members or the number of ring carbon atoms can range from 3 to 5, 3 to 6, or 3 to 7.
  • Cycloalkyl groups further include polycyclic cycloalkyl groups such as, but not limited to, norbornyl, adamantyl, bornyl, camphenyl, isocamphenyl, and carenyl groups, and fused rings such as, but not limited to, decalinyl, and the like. Cycloalkyl groups also include rings that are substituted with straight or branched chain alkyl groups as defined above.
  • Representative substituted cycloalkyl groups can be mono- substituted or substituted more than once, such as, but not limited to, 2,2-, 2,3-, 2,4- 2,5- or 2,6-disubstituted cyclohexyl groups or mono-, di- or tri-substituted norbornyl or cycloheptyl groups, which can be substituted with, for example, amino, hydroxy, cyano, carboxy, nitro, thio, alkoxy, and halogen groups.
  • the terms“carbocyclic” and“carbocycle” denote a ring structure wherein the atoms of the ring are carbon.
  • the carbocycle can have 3 to 8 ring membersor the number of ring carbon atoms can be 4, 5, 6, or 7.
  • the carbocyclic ring can be substituted with as many as N substituents wherein N is the size of the carbocyclic ring with for example, amino, hydroxy, cyano, carboxy, nitro, thio, alkoxy, and halogen groups.
  • (Cycloalkyl)alkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of the alkyl group is replaced with a bond to a cycloalkyl group as defined above,
  • Alkenyl groups include straight and branched chain and cyclic alkyl groups as defined above, except that at least one double bond exists between two carbon atoms. Thus, alkenyl groups have from 2 to about 20 carbon atoms, from 2 to 12 carbons or from 2 to 8 carbon atoms.
  • Examples include, but are not limited to —CH ⁇ CH(CH 3 ), —CH ⁇ C(CH 3 ) 2 , —C(CH 3 ) ⁇ CH 2 , —C(CH3) ⁇ CH(CH3), —C(CH2CH3) ⁇ CH2, vinyl, cyclohexenyl, cyclopentenyl, cyclohexadienyl, butadienyl, pentadienyl, and hexadienyl among others.
  • cycloalkenyl alone or in combination denotes a cyclic alkenyl group wherein at least one double bond is present in the ring structure.
  • Cycloalkenyl groups include cycloalkyl groups having at least one double bond between two adjacent carbon atoms.
  • cycloalkenyl groups include but are not limited to cyclohexenyl, cyclopentenyl, and cyclohexadienyl groups.
  • (Cycloalkenyl)alkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of the alkyl group is replaced with a bond to a cycloalkenyl group as defined above.
  • Alkynyl groups include straight and branched chain alkyl groups, except that at least one triple bond exists between two carbon atoms.
  • alkynyl groups have from 2 to about 20 carbon atoms, and typically from 2 to 12 carbons or from 2 to 8 carbon atoms. Examples include, but are not limited to —C ⁇ CH,—C ⁇ C(CH3),—C ⁇ C(CH2CH3),—CH2C ⁇ CH,—CH2C ⁇ C(CH3), and —CH 2 C ⁇ C(CH 2 CH 3 ), among others.
  • Aryl groups are cyclic aromatic hydrocarbons that do not contain heteroatoms.
  • aryl groups include, but are not limited to, phenyl, azulenyl, heptalenyl, biphenyl, indacenyl, fluorenyl, phenanthrenyl, triphenylenyl, pyrenyl, naphthacenyl, chrysenyl, biphenylenyl, anthracenyl, and naphthyl groups.
  • Aryl groups can contain 6-14 carbons in the ring portions of the groups.
  • aryl groups includes groups containing fused rings, such as fused aromatic- aliphatic ring systems (e.g., indanyl, tetrahydronaphthyl, flourene and the like), and also includes substituted aryl groups that have other groups, including but not limited to alkyl, halo, amino, hydroxy, cyano, carboxy, nitro, thio, or alkoxy groups, bonded to one of the ring atoms.
  • fused aromatic- aliphatic ring systems e.g., indanyl, tetrahydronaphthyl, flourene and the like
  • substituted aryl groups that have other groups, including but not limited to alkyl, halo, amino, hydroxy, cyano, carboxy, nitro, thio, or alkoxy groups, bonded to one of the ring atoms.
  • Representative substituted aryl groups can be mono-substituted or substituted more than once, such as, but not limited to, 2-, 3-, 4-, 5-, or 6-substituted phenyl or naphthyl groups, which can be substituted with groups including but not limited to those listed above.
  • Aralkyl or arylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to an aryl group as defined above.
  • Representative aralkyl groups include benzyl and phenylethyl groups and fused (cycloalkylaryl)alkyl groups such as 4-ethyl-indanyl.
  • the aryl moiety or the alkyl moiety or both are optionally substituted with other groups, including but not limited to alkyl, halo, amino, hydroxy, cyano, carboxy, nitro, thio, or alkoxy groups.
  • Aralkenyl group are alkenyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to an aryl group as defined above.
  • Heterocyclyl groups include aromatic and non-aromatic ring compounds containing 3 or more ring members, of which one or more is a heteroatom such as, but not limited to, N, O, S, or P.
  • Heteroaryl and heterocyclicalkyl groups are included in the definition of heterocyclyl.
  • Heterocyclyl groups can include 3 to 20 ring members, whereas other such groups can have 3 to 15 ring members. At least one ring contains a heteroatom, but every ring in a polycyclic system need not contain a heteroatom.
  • a dioxolanyl ring and a benzdioxolanyl ring system are both heterocyclyl groups within the meaning herein.
  • a heterocyclyl group designated as a C 2 -heterocyclyl can be a 5-ring with two carbon atoms and three heteroatoms, a 6-ring with two carbon atoms and four heteroatoms and so forth.
  • a C 4 -heterocyclyl can be a 5-ring with one heteroatom, a 6-ring with two heteroatoms, and so forth. The number of carbon atoms plus the number of heteroatoms sums up to equal the total number of ring atoms.
  • the heterocyclyl can be a single ring. Or the heterocyclyl can be a fusion of two or three rings.
  • the phrase“heterocyclyl group” includes fused ring species including those having fused aromatic and non-aromatic groups.
  • the phrase also includes polycyclic ring systems containing a heteroatom such as, but not limited to, quinuclidyl and also includes heterocyclyl groups that have substituents, including but riot limited to alkyl, halo, amino, hydroxy, cyano, carboxy, nitro, thio, or alkoxy groups, bonded to one of the ring members.
  • a heterocyclyl group as defined herein can be a heteroaryl group or a partially or completely saturated cyclic group including at least one ring heteroatom.
  • Heterocyclyl groups include, but are not limited to, pyrrolidinyl, furanyl, tetrahydrofuranyl, dioxolanyl, piperidinyl, piperazinyl, morpholinyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridinyl, thiophenyl, benzothiophenyl, benzofuranyl, dihydrobenzofuranyl, indolyl, dihydroindolyl, azaindolyl, indazolyl, benzimidazolyl, azabenzimidazolyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, imi
  • Heterocyclyl groups can be substituted.
  • Representative substituted heterocyclyl groups can be mono-substituted or substituted more than once, including but not limited to, rings containing at least one heteroatom which are mono, di, tri, tetra, penta, hexa, or higher-substituted with substituents such as those listed above, including but not limited to alkyl, halo, amino, hydroxy, cyano, carboxy, nitro, thio, and alkoxy groups.
  • Heteroaryl groups are aromatic ring compounds containing 5 or more ring members, of which, one or more is a heteroatom such as, but not limited to, N, O, and S.
  • a heteroaryl group designated as a C2-heteroaryl can be a 5-ring with two carbon atoms and three heteroatoms, a 6-ring with two carbon atoms and four heteroatoms and so forth.
  • a C4-heteroaryl can be a 5-ring with one heteroatom, a 6-ring with two heteroatoms, and so forth. The number of carbon atoms plus the number of heteroatoms sums up to equal the total number of ring atoms.
  • Heteroaryl groups include, but are not limited to, groups such as pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridinyl, thiophenyl, benzothiophenyl, benzofuranyl, indolyl, azaindolyl, indazolyl, benzirnidazolyl, azabenzirnidazolyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, imidazopyridinyl, isoxazolopyridinyl, thianaphthalenyl, purinyl, xanthinyl, adeninyl, guaninyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, quinoxaliny
  • heteroaryl and“heteroaryl groups” include fused ring compounds such as wherein at least one ring, but not necessarily all rings, are aromatic, including tetrahydroquinolinyl, tetrahydroisoquinolinyl, indolyl and 2,3-dihydro indolyl.
  • the term also includes heteroaryl groups that have other groups bonded to one of the ring members, including but not limited to alkyl, halo, amino, hydroxy, cyano, carboxy, nitro, thio, or alkoxy groups.
  • Representative substituted heteroaryl groups can be substituted one or more times with groups such as those listed above.
  • aryl and heteroaryl groups include but are not limited to phenyl, biphenyl, indenyl, naphthyl (1-naphthyl, 2-naphthyl), N- hydroxytetrazolyl, N-hydroxytriazolyl, N-hydroxyimidazolyl, anthracenyl (1- anthracenyl, 2-anthracenyl, 3-anthracenyl), thiophenyl (2-thienyl, 3-thienyl), furyl (2-furyl, 3-furyl), indolyl, oxadiazolyl, isoxazolyl, quinazolinyl, fluorenyl, xanthenyl, isoindanyl, benzhydryl, acridinyl, thiazolyl, pyrrolyl (2-pyrrolyl), pyrazolyl (3- pyrazolyl), imidazolyl(1-imidazo
  • Heterocyclylalkyl groups are cyclic alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a heterocyclyl group as defined above.
  • Representative heterocyclyl alkyl groups include, but are not limited to, furan-2-yl methyl, furan-3-yl methyl, pyridine-2-yl methyl ( ⁇ -picolyl), pyridine-3-yl methyl ( ⁇ -picolyl), pyridine-4-yl methyl ( ⁇ -picolyl), tetrahydrofuran-2-yl ethyl, and indol-2-ylpropyl.
  • Heterocyclylalkyl groups can be substituted on the heterocyclyl moiety, the alkyl moiety, or both.
  • Heterocyclylalkyl groups may be Heterocyclylmethyl groups.
  • Heterocyclylalkyl groups may be heteroarylalkyl groups.
  • Heterocyclylalkyl maybe optionally substituted.
  • Heteroarylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a heteroaryl group as defined above. Heteroarylalkyl groups can be substituted on the heteroaryl moiety, the alkyl moiety, or both. Heteroarylalkyl maybe optionally substituted.
  • a“ring system” or“ring,” as the term is used herein, is meant a moiety comprising one, two, three or more rings, which can be substituted with non-ring groups or with other ring systems, or both, which can be fully saturated, partially unsaturated, fully unsaturated, or aromatic, and when the ring system includes more than a single ring, the rings can be fused, bridging, or spirocyclic.
  • spirocyclic is meant the class of structures wherein two rings are fused at a single tetrahedral carbon atom, as is well known in the art.
  • A“monocyclic, bicyclic or polycyclic, aromatic or partially aromatic ring” as the term is used herein refers to a ring system including an unsaturated ring possessing 4n+2 pi electrons, or a partially reduced (hydrogenated) form thereof.
  • the aromatic or partially aromatic ring can include additional fused, bridged, or Spiro rings that are not themselves aromatic or partially aromatic.
  • naphthalene and tetrahydronaphthalene are both a “monocyclic, bicyclic or polycyclic, aromatic or partially aromatic ring” within the meaning herein.
  • a benzo-[2.2.2]-bicyclooctane is also a“monocyclic, bicyclic or polycyclic, aromatic or partially aromatic ring” within the meaning herein, containing a phenyl ring fused to a bridged bicyclic system.
  • a fully saturated ring has no double bonds therein, and is carbocyclic or heterocyclic depending on the presence of heteroatoms within the meaning herein.
  • alkoxy refers to an oxygen atom connected to an alkyl group, including a cycloalkyl group, as are defined above.
  • linear alkoxy groups include but are not limited to methoxy, ethoxy, n-propoxy, n-butoxy, n-pentyloxy, n-hexyloxy, and the like.
  • branched alkoxy include but are not limited to isopropoxy, sec-butoxy, tert-butoxy, isopentyloxy, isohexyloxy, and the like.
  • cyclic alkoxy include but are not limited to cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like.
  • aryloxy and“arylalkoxy” refer to, respectively, an aryl group bonded to an oxygen atom and an aralkyl group bonded to the oxygen atom at the alkyl moiety. Examples include but are not limited to phenoxy, naphthyloxy, and benzyloxy.
  • An“acyl” group as the term is used herein refers to a group containing a carbonyl moiety wherein the group is bonded via the carbonyl carbon atom.
  • the carbonyl carbon atom is also bonded to another carbon atom, which can be part of an alkyl, aryl, aralkyl cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl group or the like.
  • the group is a“formyl” group
  • an acyl group as the term is defined herein.
  • An acyl group can include 0 to about 12-20 additional carbon atoms bonded to the carbonyl group.
  • An acyl group can include double or triple bonds within the meaning herein.
  • An acryloyl group is an example of an acyl group.
  • An acyl group can also include heteroatoms within the meaning here.
  • a nicotinoyl group (pyridyl-3-carbonyl) group is an example of an acyl group within the meaning herein.
  • Other examples include acetyl, benzoyl, phenylacetyl, pyridylacetyl, cinnamoyl, and acryloyl groups and the like.
  • the group containing the carbon atom that is bonded to the carbonyl carbon atom contains a halogen, the group is termed a“haloacyl” group.
  • An example is a trifluoroacetyl group.
  • amine or“amino” includes primary, secondary, and tertiary amines having, e.g., the formula N(group) 3 wherein each group can independently be H or non-H, such as alkyl, aryl, and the like.
  • Amines include but are not limited to R—NH 2 , for example, alkylamines, arylamines, alkylarylamines; dialkylarnines, diarylamines, aralkylamines, heterocyclylamines and the like; and trialkylamines, dialkylarylamines, alkyldiarylamines, triarylamines, and the like.
  • Each alkyl in a dialkylamine and trialkylamine may be independentyl selected.
  • Dialkylamine and trialkylamine includes amines having an aryl and an alkyl.
  • the term“amine” also includes ammonium ions as used herein.
  • An“amine” or“amino” includes a substituent of the form—NH 2 ,—NHR,—N(R) 2 ,—N(R) 3 + , wherein each R is independently selected, and protonated forms of each. Accordingly, any compound substituted with an amino group can be viewed as an amine.
  • An“ammonium” ion includes the unsubstituted ammonium ion NH 4 + , but unless otherwise specified, it also includes any protonated or quaternarized forms of amines. Thus, trimethylammonium hydrochloride and tetramethylammonium chloride are both ammonium ions, and amines, within the meaning herein.
  • amide includes C- and N-amide groups, i.e.,—C(O)N(R) 2 , and—NRC(O)R-groups, respectively.
  • Amide groups therefore include substituted and unsubstituted amide groups. Amide groups therefore include but are not limited to carbamoyl groups (—C(O)NH 2 ) and formamide groups (—NHC(O)H).
  • a “carboxamido” group is a group of the formula C(O)N(R)2, wherein R can be H, alkyl, aryl, etc.
  • an“alkylamido” substituent contains an alkyl group linked to a–C(O)NH- moiety which is attached to the substituted compound via the nitrogen and is linked to the alkyl group via the carbonyl.
  • an“amidoalkyl” substituent contains an alkyl group linked to a–NHC(O)- moiety which is attached to the substituted compound via the carbonyl and linked to the alkyl group via the nitrogen.
  • an “alkenylamido” substituent contains an alkenyl group linked to a–C(O)NH- moiety which is attached to the substituted compound via the nitrogen and is linked to the alkyl group via the carbonyl.
  • an“amidoalkenyl” substituent contains an alkenyl group linked to a–NHC(O)- moiety which is attached to the substituted compound via the carbonyl and linked to the alkyl group via the nitrogen.
  • Alkylamido, amidoalkyl, alkenylamido, and amidoalkenyl groups described herein may include include 2 to 20 carbons, 2 to 10 carbons, 2 to 8 carbons, 2 to 5 carbons, 2 to 4 carbons, 2 to 3 carbons or 2 carbons. Each such group may be further optionally substituted.
  • urea includes e.g.,—NHC(O)NH—,—NHC(O)NH—, —NHC(O)NR— and—NRC(O)NR— groups, respectively.
  • Urea groups therefore include substituted and unsubstituted urea groups.
  • an“alkylurea” substituent contains an alkyl group linked to a urea moiety which is attached to the substituted compound via a nitrogen and is linked to the alkyl group via the other nitrogen.
  • an“alkenylurea” substituent contains an alkenyl group linked to a urea moiety which is attached to the substituted compound via a nitrogen and is linked to the alkenyl group via the other nitrogen.
  • Alkylurea and alkenylurea groups described herein may include include 2 to 20 carbons, 2 to 10 carbons, 2 to 8 carbons, 2 to 5 carbons, 2 to 4 carbons, 2 to 3 carbons or 2 carbons. Each such group may be further optionally substituted.
  • urethane includes N- and O-urethane groups, i.e.,—NRC(O)OR and—OC(O)N(R) 2 groups, respectively.
  • sulfonamide includes S- and N- sulfonamide groups, i.e., —SO2NR2 and —NRSO2R groups, respectively.
  • Sulfonamide groups therefore include but are not limited to sulfamoyl groups (— SO2NH2)
  • a dialkylaminosulfonyl group contains two independently selected alkyl groups, which may be the same or different.
  • a dialkylaminosulfonyl group includes a group having one or more aryl in place of the alkyl group.
  • a dialkylaminosulfonyl group also includes groups where the two alkyl’s are linked to form a ring together with the amine to which they are attached.
  • the term“amidine” or“amidino” includes groups of the formula— C(NR)N(R) 2 . Typically, an amidino group is—C(NH)NH 2 .
  • the term“guanidine” or“guanidino” includes groups of the formula —NRC(NR)N(R) 2 . Typically, a guanidine group is—NHC(NH)NH 2 .
  • Halo “Halo,”“halogen,” and“halide” include fluorine, chlorine, bromine and iodine.
  • A“salt” as is well known in the art includes an organic compound such as a carboxylic acid, a sulfonic acid, or an amine, in ionic form, in combination with a counterion.
  • acids in their anionic form can form salts with cations such as metal cations, for example sodium, potassium, and the like; with ammonium salts such as NH4 + or the cations of various amines, including tetraalkyl ammonium salts such as tetramethylammonium, or other cations such as trimethylsulfonium, and the like.
  • A“pharmaceutically acceptable” or“pharmacologically acceptable” salt is a salt formed from an ion that has been approved for human consumption and is generally non-toxic, such as a chloride salt or a sodium salt.
  • A“zwitterion” is an internal salt such as can be formed in a molecule that has at least two ionizable groups, one forming an anion and the other a cation, which serve to balance each other. For example, amino acids such as glycine can exist in a zwitterionic form.
  • A“zwitterion” is a salt within the meaning herein.
  • the compounds of the present disclosure may take the form of salts.
  • the term“salts” embraces addition salts of free acids or free bases which are compounds .
  • Salts can be“pharmaceutically-acceptable salts.”
  • pharmaceutically-acceptable salt refers to salts which possess toxicity profiles within a range that affords utility in pharmaceutical applications. Pharmaceutically unacceptable salts may nonetheless possess properties such as high crystallinity, which have utility in the practice of the present disclosure, such as for example utility in process of synthesis, purification or formulation of compounds .
  • Suitable pharmaceutically-acceptable acid addition salts may be prepared from an inorganic acid or from an organic acid.
  • inorganic acids include hydrochloric, hydrobrornic, hydriodic, nitric, carbonic, sulfuric, and phosphoric acids.
  • Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, examples of which include formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, trifluoromethanesulfonic, 2- hydroxyethanesulfonic, p-toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, stearic, alginic, ⁇ -hydroxybutyric
  • Suitable pharmaceutically acceptable base addition salts of compounds include, for example, metallic salts including alkali metal, alkaline earth metal and transition metal salts such as, for example, calcium, magnesium, potassium, sodium and zinc salts.
  • Pharmaceutically acceptable base addition salts also include organic salts made from basic amines such as, for example, N,N ⁇ -dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine.
  • Examples of pharmaceutically unacceptable base addition salts include lithium salts and cyanate salts.
  • salts may be useful, for example as intermediates in the synthesis of Formula I or II compounds, for example in their purification by recrystallization. All of these salts may be prepared by conventional means from the corresponding compound. according to Formula I or II by reacting, for example, the appropriate acid or base with the compound according to Formula I or II.
  • pharmaceutically acceptable salts refers to nontoxic inorganic or organic acid and/or base addition salts, see, for example, Lit et al., Salt Selection for Basic Drugs (1986), Int J. Pharm., 33, 201-217, incorporated by reference herein.
  • A“hydrate” is a compound that exists in a composition with water molecules.
  • the composition can include water in stoichiometric quantities, such as a monohydrate or a dihydrate, or can include water in random amounts.
  • a“hydrate” refers to a solid form, i.e., a compound in water solution, while it may be hydrated, is nota hydrate as the term is used herein.
  • A“solvate” is a similar composition except that a solvent other that water replaces the water.
  • a solvent other that water replaces the water.
  • methanol or ethanol can form an “alcoholate”, which can again be stoichiometric or non-stoichiometric.
  • a“solvate” refers to a solid form, i.e., a compound in solution in a solvent, while it may be solvated, is not a solvate as the term is used herein.
  • A“prodrug” as is well known in the art is a substance that can be administered to a patient where the substance is converted in vivo by the action of biochemicals within a mammal's body (e.g., in a patient's body), such as enzymes, to the active pharmaceutical ingredient.
  • examples of prodrugs include esters of carboxylic acid groups, which can be hydrolyzed by endogenous esterases as are found in the bloodstream of humans and other mammals.
  • compounds described herein may be prepared using a number of methods known in the chemical arts, in light of the description contained herein, in combination with the knowledge of the skilled artisan.
  • Various starting materials, intermediates, and reagents may be purchased from commercial sources or made according to literature methods or adaptations thereof.
  • the starting materials used for the synthesis of compounds described herein can be obtained from commercial sources, such as Aldrich Chemical Co. (Milwaukee, Wis.), Sigma Chemical Co. (St. Louis, Mo.), or the starting materials can be synthesized.
  • Compounds contemplated herein include, but are not limited to, the compounds described generically herein and those listed in Table 1 and Table 2, and pharmaceutically acceptable salts or prodrugs thereof.
  • XBP1 is believed to sustain dendritic cell immunosuppressive activity with the tumor microenvironment by directly upregulating enzymes involved in triglyceride biosynthesis (Cubillos-Ruiz, et al., Cell 161(7): 1527-38 (2015)).
  • XBP1 also known as X-box binding protein 1
  • IRE1 ⁇ -mediated XBP1 activation was fueled by the induction of reactive oxygen species and subsequent formation of peroxidized lipids.
  • IRE1 ⁇ The most conserved arm of the endoplasmic reticulum (ER) stress response is the dual enzyme, IRE1 ⁇ . Activated during periods of ER stress, the IRE1 ⁇ endoribonuclease domain excises a short nucleotide fragment from Xbp1 mRNA to generate the functional transcription factor, XBP1.
  • This potent, multitasking protein promotes cell survival by upregulating expression of a broad range of critical genes involved in protein folding and quality control.
  • XBP1 drives the pathogenesis of triple negative breast cancer (TNBC) by promoting tumor cell survival and metastatic capacity under hypoxic conditions. Silencing of XBP1 in TNBC leads to suppression of tumor initiation, progression, and recurrence.
  • TNBC triple negative breast cancer
  • XBP1 promotes tumor progression: by confounding the development of protective antitumor immunity in the ovarian cancer tumor microenvironment.
  • tumor resident dendritic cells failed to accumulate intracellular lipids, which normally disrupt effective antigen cross-presentation.
  • This pathological lipid accumulation is fundamentally driven by reactive oxygen species-mediated lipid peroxidation, which directly destabilizes protein-folding chaperones within the endoplasmic reticulum to induce a state of ER stress and XBP1 activation.
  • IRE1 ⁇ -mediated XBP1 signaling is also critical for myeloid cell production of immunosuppressive prostaglandins such as prostaglandin E2 (PGE2).
  • Novel small-molecule IRE1 ⁇ inhibitors with the ability to induce two parallel and mutually reinforcing anti-tumor mechanisms, namely the direct inhibition of tumor growth and the simultaneous induction of robust anti-tumor immunity, are highly desirable, as no effective, targeted therapies currently exist for either TNBC or ovarian cancer.
  • the compositions and methods described herein are novel IRE1 ⁇ kinase inhibitors that exhibit immune-modulatory properties. No currently existing compounds possess activity in the presence of human or mouse ovarian cancer ascites, a critical requirement for IRE1 ⁇ inhibitor usage clinically.
  • Novel direct and indirect small molecule IRE1 ⁇ inhibitors can prevent lipid accumulation in myeloid cells exposed to ovarian cancer-derived ascites supernatants. Furthermore, the identified direct IRE1 ⁇ inhibitors have unique chemical structures compared to currently available compounds, and therefore can have unique binding mechanisms, inhibitory activity, and off-target effects. Additionally, the inventors have demonstrated that these compounds block myeloid cell immunosuppression mediated by tumor-associated factors. The disclosure also includes novel uses for vitamin E and hydralazine derivatives, which indirectly prevent IRE1 ⁇ activation and thereby suppress cancer cell- induced lipid accumulation in myeloid dendritic cells.
  • the IRE1 ⁇ -XBP1 pathway is therefore involved in a variety of pathological conditions, including neurodegenerative diseases, inflammation, metabolic disorders, liver dysfunction, brain ischemia, heart ischemia, autoimmune diseases, and cancer. Hence, modulation of this pathway provides therapeutic methods useful for treatment of such diseases.
  • the identified small molecule compounds can, for example, be employed as therapeutic compounds that enhance dendritic cell and T cell anti-tumor activity in mammals.
  • the compounds disclosed herein can be used to treat murine and human ovarian cancers.
  • a method is described herein that includes administering any of the compounds or the composition described herein.
  • the mammal can be in need of administration of the composition.
  • the mammal can have cancer, a neurodegenerative disease, inflammation, a metabolic disorder, liver dysfunction, brain ischemia, heart ischemia, or an autoimmune disease.
  • the mammal has triple negative breast cancer or ovarian cancer.
  • the IRE1 ⁇ inhibitor compounds, their pharmaceutically acceptable salts or hydrolyzable esters of the present disclosure may be corribined with a pharmaceutically acceptable carrier to provide pharmaceutical compositions useful for treating the biological conditions or disorders noted herein in mammalian species, and more preferably, in humans.
  • a pharmaceutically acceptable carrier to provide pharmaceutical compositions useful for treating the biological conditions or disorders noted herein in mammalian species, and more preferably, in humans.
  • the particular carrier employed in these pharmaceutical compositions may vary depending upon the type of administration desired (e.g. intravenous, oral, topical, suppository, or parenteral).
  • compositions in oral liquid dosage forms e.g. suspensions, elixirs and solutions
  • typical pharmaceutical media such as water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like
  • carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like can be employed.
  • compositions of the compounds alone or in combination with another IRE1 ⁇ inhibitor or another type of therapeutic agent, or both.
  • the compositions and methods described herein can include one or more agents such as vitamin E, an antioxidant, and/or hydralazine.
  • agents can sequester lipid peroxidation byproducts, and can be effective treatments for controlling ER stress responses and sustained IRE1 ⁇ /XBP1 signaling in tumor-associated dendritic cells exposed, for example, to ovarian cancer-derived ascites.
  • compositions containing a compound can be prepared by conventional techniques, e.g. as described in Remington: The Science and Practice of Pharmacy, 19th Ed., 1995, incorporated by reference herein.
  • the compositions can appear in conventional forms, for example capsules, tablets, aerosols, solutions, suspensions or topical applications.
  • compositions include one or more compounds and a pharmaceutically acceptable excipient which can be a carrier or a diluent.
  • the active compound will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which can be in the form of an ampoule, capsule, sachet, paper, or other container.
  • the active compound when mixed with a carrier, or when the carrier serves as a diluent, it can be solid, semi-solid, or liquid material that acts as a vehicle, excipient, or medium for the active compound.
  • the active compound can be adsorbed on a granular solid carrier, for example contained in a sachet.
  • suitable carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, peanut oil, olive oil, gelatin, lactose, terra alba, sucrose, dextrin, magnesium carbonate, sugar, cyclodextrin, amylose, magnesium stearate, talc, gelatin, agar, pectin, acacia, stearic acid or lower alkyl ethers of cellulose, silicic acid, fatty acids, fatty acid amines, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, polyoxyethylene, hydroxymethylcellulose and polyvinylpyrrolidone.
  • the carrier or diluent can include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.
  • the formulations can be nixed with auxiliary agents which do not deleteriously react with the active compounds.
  • auxiliary agents which do not deleteriously react with the active compounds.
  • Such additives can include wetting agents, emulsifying and suspending agents, salt for influencing osmotic pressure, buffers and/or coloring substances preserving agents, sweetening agents or flavoring agents.
  • the compositions can also be sterilized if desired.
  • the route of administration can be any route which effectively transports the active compound which inhibits the activity of the IRE1 ⁇ to the appropriate or desired site of action, such as oral, nasal, pulmonary, buccal, subdermal, intradermal, transdermal or parenteral, e.g., rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular, intranasal, ophthalmic solution or an ointment, the oral route being preferred.
  • the carrier will typically comprise sterile water, although other ingredients that aid solubility or serve as preservatives can also be included.
  • injectable suspensions can also be prepared, in which case appropriate liquid carriers, suspending agents and the like can be employed.
  • the compounds described herein can be formulated using bland, moisturizing bases such as ointments or creams.
  • the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or it can be in the form of a troche or lozenge. If a liquid carrier is used, the preparation can be in the form of a syrup, emulsion, soft gelatin capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
  • Injectable dosage forms generally include aqueous suspensions or oil suspensions which can be prepared using a suitable dispersant or wetting agent and a suspending agent Injectable forms can be in solution phase or in the form of a suspension, which is prepared with a solvent or diluent.
  • Acceptable solvents or vehicles include sterilized water, Ringer's solution, or an isotonic aqueous saline solution.
  • sterile oils can be employed as solvents or suspending agents.
  • the oil or fatty acid is non-volatile, including natural or synthetic oils, fatty acids, mono-, di- or tri-glycerides.
  • the formulation can also be a powder suitable for reconstitution with an appropriate solution as described above. Examples of these include, but are not limited to, freeze dried, rotary dried or spray dried powders, amorphous powders, granules, precipitates, or particulates.
  • the formulations can optionally contain stabilizers, pH modifiers, surfactants, bioavailability modifiers and combinations of these.
  • the compounds can be formulated for parenteral administration by injection such as by bolus injection or continuous infusion.
  • a unit dosage form for injection can be in ampoules or in multi-dose containers.
  • the formulations can be designed to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.
  • the formulations can also be formulated for controlled release or for slow release.
  • compositions contemplated herein can include, for example, micelles or liposomes, or some other encapsulated form, or can be administered in an extended release form to provide a prolonged storage and/or delivery effect. Therefore, the formulations can be compressed into pellets or cylinders and implanted intramuscularly or subcutaneously as depot injections. Such implants can employ known inert materials such as silicones and biodegradable polymers, e.g., polylactide-polyglycolide. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides).
  • the preparation can contain a compound which inhibits the enzymatic activity of the focal adhesion kinase, dissolved or suspended in a liquid carrier, preferably an aqueous carrier, for aerosol application.
  • a liquid carrier preferably an aqueous carrier
  • the carrier can contain additives such as solubilizing agents, e.g., propylene glycol, surfactants, absorption enhancers such as lecithin (phosphatidylcholine) or cyclodextrin, or preservatives such as parabens.
  • injectable solutions or suspensions preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.
  • Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application.
  • Preferable carriers for tablets, dragees, or capsules include lactose, corn starch, and/or potato starch.
  • a syrup or elixir can be used in cases where a sweetened vehicle can be employed.
  • a typical tablet that can be prepared by conventional tableting techniques can contain:
  • a typical capsule for oral administration contains compounds (250 mg), lactose (75 mg) and magnesium stearate (15 mg). The mixture is passed through a 60-mesh sieve and packed into a No, 1 gelatin capsule.
  • a typical injectable preparation is produced by aseptically placing 250 mg of compounds into a vial, aseptically freeze-drying and sealing. For use, the contents of the vial are mixed with 2 mL of sterile physiological saline, to produce an injectable preparation.
  • the compounds can be administered to a human in need of such treatment, prevention, elimination, alleviation or amelioration of a malcondition that is mediated through the action of IRE1 ⁇ , for example, cancer, neurodegenerative diseases, inflammation, metabolic disorders, liver dysfunction, brain ischemia, or heart ischemia.
  • a malcondition that is mediated through the action of IRE1 ⁇ , for example, cancer, neurodegenerative diseases, inflammation, metabolic disorders, liver dysfunction, brain ischemia, or heart ischemia.
  • compositions and compounds described herein can generally be administered in the form of a dosage unit (e.g. tablet, capsule, etc.) in an amount from about 1 ng/kg of body weight to about 0.5 g/kg of body weight, or from about 1 ⁇ /kg of body weight to about 500 mg/kg of body weight, or from about 10 ⁇ /kg of body weight to about 250 mg/kg of body weight, most preferably from about 20 ⁇ /kg of body weight to about 100 mg/kg of body weight.
  • a dosage unit e.g. tablet, capsule, etc.
  • the compounds are effective over a wide dosage range. For example, in the treatment of adult humans, dosages from about 0.05 to about 5000 mg, preferably from about 1 to about 2000 mg, and more preferably between about 2 and about 2000 mg per day can be used. A typical dosage is about 10 mg to about 1000 mg per day. In choosing a regimen for patients it can frequently be necessary to begin with a higher dosage and when the condition is under control to reduce the dosage. The exact dosage will depend upon the activity of the compound, mode of administration, on the therapy desired, form in which administered, the subject to be treated and t body weight of the subject to be treated, and the preference and experience of the physician or veterinarian in charge.
  • IRE1 ⁇ inhibitor bioactivity of the compounds can be determined by use of an in vitro assay system which measures the activity of IRE1 ⁇ , which can be expressed as EC 50 or IC 50 values, as are well known in the art inhibitors can be determined by the method described in the Examples.
  • the compounds are dispensed in unit dosage form including from about 0.05 mg to about 1000 mg of active ingredient together with a pharmaceutically acceptable carrier per unit dosage.
  • dosage forms suitable for oral, nasal, pulmonal or transdermal administration include from about 125 ⁇ g to about 1250 mg, preferably from about 250 ⁇ g to about 500 mg, and more preferably from about 2.5 mg to about 250 mg, of the compounds admixed with a pharmaceutically acceptable carrier or diluent.
  • Dosage forms can be administered daily, or more than once a day, such as twice or thrice daily. Alternatively, dosage forms can be administered less frequently than daily, such as every other day, or weekly, if found to be advisable by a prescribing physician.
  • Prodrugs of a compound which, on administration, undergo chemical conversion by metabolic or other physiological processes before becoming active pharmacological substances are contemplated herein. Conversion by metabolic or other physiological processes includes without limitation enzymatic (e.g, specific enzymatically catalyzed) and non-enzymatic (e.g., general or specific acid or base induced) chemical transformation of the prodrug into the active pharmacological substance.
  • enzymatic e.g, specific enzymatically catalyzed
  • non-enzymatic e.g., general or specific acid or base induced
  • compositions of a compound described herein including formulating a compound with a pharmaceutically acceptable carrier or diluent.
  • the pharmaceutically acceptable carrier or diluent is suitable for oral administration.
  • the methods can further include the step of formulating the composition into a tablet or capsule.
  • the pharmaceutically acceptable carrier or diluent is suitable for parenteral administration.
  • the methods can further include the step of lyophilizing the composition to form a lyophilized preparation.
  • the compounds can be used therapeutically in combination with i) one or more other IRE1 ⁇ inhibitors and/or ii) one or more other types of protein kinase inhibitors and/or one or more other types of therapeutic agents which can be administered orally in the same dosage form, in a separate oral dosage form (e.g., sequentially or non-sequentially) or by injection together or separately (e.g., sequentially or non-sequentially).
  • agents or medicaments adapted for treatment of a disease or malcondition for which inhibition of IRE1 ⁇ is medically indicated for example, vitamin E, an antioxidant, hydralazine, or any combination thereof.
  • Such compounds, agents or medicaments can be medically indicated for treatment of cancers such as TNBC or ovarian cancer, neurodegenerative diseases, inflammation, metabolic disorders, liver dysfunction, autoimmune diseases, brain ischernia, or heart ischemic.
  • Combinations include mixtures of compounds from (a) and (b) in a single formulation and compounds from (a) and (b) as separate formulations. Some combinations can be packaged as separate formulations in a kit. Two or more compounds from (b) can be formulated together while another compound can be formulated separately.
  • both vitamin E and hydralazine suppressed pathological intracellular lipid accumulation in myeloid dendritic cells exposed to ovarian cancer ascites supernatants (FIG. 1). Based on the strong evidence linking aberrant lipid accumulation myeloid cell immunosuppression, these agents can be used to restore the function of antigen presenting cells in the tumor microenvironment.
  • compositions and methods described herein can include one or more direct, small molecule IRE1 ⁇ inhibitors.
  • IRE1 ⁇ is a dual enzyme, containing a kinase and endoribonuclease domain. Phosphorylation of the kinase domain during times of ER stress leads to activation of the endoribonuclease domain and subsequent Xbp1 splicing, indicating that small molecules designed to block either the kinase domain or the endoribonuclease domain are feasible inhibitory strategies.
  • FRET Förster resonance energy transfer
  • a small XBP1-mimetic RNA hairpin containing sequence features required for IRE1 ⁇ -mediated splicing has been synthesized with the fluorophore 6FAM attached to the 5 ⁇ end and the quenching dye Black Hole Quencher 1 (BHQ1) attached to the 3 ⁇ end.
  • BHQ1 Black Hole Quencher 1
  • IRE1 ⁇ -mediated cleavage of the RNA hairpin leads to an increase in the fluorescence signal.
  • the inventors also incorporated a point mutant version of this same RNA hairpin that is resistant to IRE1 ⁇ -mediated cleavage to control for non-specific RNAse contamination (FIG.2).
  • cytoplasmic domain of human IRE1 ⁇ (approximately residues 465-977) has been crystallized five separate times (PDBs 4PL3, 4U6R, 4PL4, 4PL5, and 3P23) in different states of phosphorylation and activation, as well as with both endoribonuclease inhibitors and kinase inhibitors (Sanches et al., Nature Communications 5:4202 (2014); Harrington et al., ACS Med Chem Letters 6:68-72 (2015); Ali et al., The EMBO J 30:894-905 (2011)).
  • IRE1 ⁇ kinase inhibitors can either inhibit or activate the IRE1 ⁇ endoribonuclease domain depending on their binding mode.
  • Type I kinase inhibitors that lock the IRE1 ⁇ kinase domain into a “DFG-out” conformation block endoribonuclease activity, while inhibitors that lock the kinase domain into a“DFG-in” conformation trigger mRNA splicing despite abrogating autophosphorylation.
  • the SRC inhibitor exhibited a good docking score using unconstrained rigid receptor docking, as its urea group made hydrogen bonds with both a serine residue N-terminal to the DFG loop and a lysine-aspartate salt bridge in the kinase active site.
  • the set of all compounds commercially available from the company eMolecules (over 7 million in sum) was used as the screening collection. From the full list of 7 million compounds, only urea and amide-containing structures were computationally docked ( ⁇ 800,000 compounds), as these motifs form key hydrogen bond interactions with kinase DFG loops. Top scoring compounds were clustered by structural similarity and filtered for those with desirable properties, and the top scoring compounds from each of 49 clusters were ordered and tested by FRET assay.
  • New small molecule compounds were designed to inhibit the human IRE1alpha kinase domain. Multiple variants of the original compound series were designed and ranked by computational docking score using the software LiveDesign. High scoring compounds were synthesized and evaluated biochemically by the IRE1 ⁇ FRET assay.
  • RNA probes Two RNA probes were used, XBP1 wildtype (CAUGUCCGCAGCACAUG; Sequence Length: 17; Sequence Type: RNA; Sequence Organism: Artificial Sequence; Synthetic Probe) which is able to be spliced by active IRE1 ⁇ or XBP1 mutant (CAUGUCCCCAGCACAUG; Sequence Length: 17; Sequence Type: RNA; Sequence Organism: Artificial Sequence; Synthetic Probe) which is unable to be spliced.
  • Each probe contained a 5 ⁇ 6-FAM modification and a 3' IOWA Black FQ modification.
  • Embodiment 1 provides a compound of Formula I,
  • the A ring is a heterocyclyl or aryl
  • x is an integer of 0-2;
  • R 1 is independently amino, C1-C4 alkyl, C1-C4 alkoxy, hydroxy, C1-C4 hydroxyalkyl, arylsulfonyl, cyano, halogen, or trifluoromethyl;
  • the linkage 1 is a single bond, C1-C3 alkyl, C2-C3 alkenyl or C2-C3 alkynyl;
  • the B ring is a heterocyclyl or aryl
  • y is an integer of 0-1;
  • R 2 is independently amino, C 1 -C 4 alkyl, halogen or trifluoromethyl
  • linkage 2 is amino, urea, amido, alkylamido, alkenylamido, amidoalkyl, amidoalkenyl, alkylurea, or alkenylurea;
  • the C ring is a heterocyclyl or aryl
  • z is an integer of 0-2;
  • R 3 is independently amino, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, hydroxy, C 1 -C 4 hydroxyalkyl, cyano, halogen, trifluoromethyl, difluoromethyl, monofluoroalkyl, benzyl, dialkylaminosulfonyl, alkylsulfonyl, boronic ester, boronic acid, dialkylphosphine, C 1 -C 4 alkylcarboxyl, dialkylamido, cycloalkylalkyl, or heterocycloalkylalkyl;
  • Embodiment 2 provides the compound of Formula I wherein the linkage 1 is a single bond.
  • Embodiment 3 provides the compound of Formula I wherein the linkage 1 is an C 1 -C 3 alkyl, C 2 -C 3 alkenyl or C 2 -C 3 alkynyl; and the linkage 2 is a urea, alkylurea, or alkenylurea.
  • Embodiment 4 provides a compound of Formula II,
  • the A ring is a heterocyclyl or aryl; x is an integer of 0-2;
  • R 1 is independently amino, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, hydroxy, C 1 -C 4 hydroxyalkyl, arylsulfonyl, cyano, halogen, or trifluoromethyl;
  • the linkage 1 is a single bond, C1-C3 alkyl, C2-C3 alkenyl or C2-C3 alkynyl;
  • the B ring is a heterocyclyl or aryl
  • y is an integer of 0-1;
  • R 2 is independently amino, C 1 -C 4 alkyl, halogen or trifluoromethyl
  • linkage 2 is amino, urea, amido, alkylamido, alkenylamido, amidoalkyl, amidoalkenyl, alkylurea, or alkenylurea;
  • G is dialkylamino or H
  • Embodiment 5 provides a compound of Formula III,
  • the A ring is a heterocyclyl or aryl
  • x is an integer of 0-2;
  • R 1 is independently amino, C1-C4 alkyl, C1-C4 alkoxy, hydroxy, C1-C4 hydroxyalkyl, arylsulfonyl, cyano, halogen, trifluoromethyl or a group having the structure , wherein the D ring is a heterocyclyl;
  • v is an integer of 0-2;
  • R D is amino, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, hydroxy, C 1 -C 4 hydroxyalkyl, arylsulfonyl, cyano, halogen, or trifluoromethyl ;
  • linkage D is a single bond, amino or C 1 -C 3 alkyl
  • the B 1 ring is a heterocyclyl or aryl
  • y is an integer of 0-1;
  • R 5 is independently amino, C1-C3 alkyl, halogen or trifluoromethyl
  • the B 2 ring is phenyl, pyridinyl, naphthyl or a bicyclic heterocyclyl
  • z is an integer of 0-1;
  • R 6 is independently amino, C 1 -C 4 alkyl, halogen or trifluoromethyl
  • the C ring is a heterocyclyl ring; w is an integer of 0-2;
  • R 3 is independently C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 hydroxyalkyl, hydroxy, aryl, benzyl, benzaldehyde, halogen, cyano, amino, heterocyclyl, heterocyclylalkyl, cycloalkyl, cycloalkylalkyl, trifluoromethyl, difluoromethyl, monofluoroalkyl, dialkylaminosulfonyl, alkylsulfonyl, dialkylphosphine, C1-C4 alkylcarboxyl, dialkylamido, or dialkylamino;
  • the linkage A is a single bond, is a C 1 -C 5 alkyl, alkenyl, alkynyl, alkylamido, acyl, or oxo(carbonyl)alkyl;
  • linkage B is alkylamido, alkenylamido, amidoalkyl, amidoalkenyl, urea, alkylurea, ureaalkyl, alkenylurea or ureaalkenyl;
  • the linkage C is (CH 2 ) n , where n is an integer of 0-3, and when n is 0, the linkage between the B 2 ring and the C ring is a single bond;
  • Embodiment 6 provides a compound of Formula III, wherein the compound of claim 5, wherein x is 1-2; and at least one of R 4 is .
  • Embodiment 7 provides a compound of Formula III, wherein w is 1-2; and at least one of R 8 is heterocyclyl, heterocyclylalkyl, cycloalkyl or cycloalkylalkyl.
  • Embodiment 8 provides a compound of Formula III, when linkage A is alkynyl and linkage B is urea, then A is aryl.
  • Embodiment 9 provides a compound of Formula III, wherein at least one of X, Y Z and W is other than 0.
  • Embodiment 10 provides a compound of any of the preceding embodiments, wherein the A ring is heteroaromatic.
  • Embodiment 11 provides a compound of any of the preceding embodiments, wherein the A ring is indazole, imadazopyridine, imadazopyrazine, imadazopyridazine, pyrrolopyridine, hexahydrothienopyrimidine, imidazole, pyrazole, pyrazine, pyridine, pyrimidine, phenylpyrimidinamine, quinolinyl, isoquinolinyl, tetrahydroquinolinyl or quinazolinyl.
  • Embodiment 12 provides a compound of any of the preceding embodiments, wherein the A ring is a single, non-fused ring.
  • Embodiment 13 provides a compound of any of the preceding embodiments, wherein the A ring is a fusion of two rings.
  • Embodiment 14 provides a compound of any of the preceding embodiments, wherein the A ring is phenyl.
  • Embodiment 15 provides a compound of any of the preceding embodiments, wherein the B ring is a heteroaromatic.
  • Embodiment 16 provides a compound of any of the preceding embodiments, wherein the B ring is indazole, imadazopyridine, imadazopyrazine, imadazopyridazine, pyrrolopyridine, hexahydrothienopyrimidine, imidazole, pyrazole, pyrazine, pyridine, pyrimidine, phenylpyrimidinamine, quinolinyl, isoquinolinyl, tetrahydroquinolinyl or quinazolinyl.
  • the B ring is indazole, imadazopyridine, imadazopyrazine, imadazopyridazine, pyrrolopyridine, hexahydrothienopyrimidine, imidazole, pyrazole, pyrazine, pyridine, pyrimidine, phenylpyrimidinamine, quinolinyl, isoquinolinyl, t
  • Embodiment 17 provides a compound of any of the preceding embodiments, wherein the B ring is pyrazolyl, imidazolyl, or triazolyl.
  • Embodiment 18 provides a compound of any of the preceding embodiments, wherein the B ring is a single, non-fused ring.
  • Embodiment 19 provides a compound of any of the preceding embodiments, wherein the B ring is a fusion of two rings.
  • Embodiment 20 provides a compound of any of the preceding embodiments, wherein the B ring is phenyl.
  • Embodiment 21 provides a compound of any of the preceding embodiments, wherein the C ring is heteroaromatic.
  • Embodiment 22 provides a compound of any of the preceding embodiments, wherein the C ring is indazole, imadazopyridine, imadazopyrazine, imadazopyridazine, pyrrolopyridine, hexahydrothienopyrimidine, imidazole, pyrazole, pyrazine, pyridine, pyrimidine, phenylpyrimidinamine, quinolinyl, isoquinolinyl, tetrahydroquinolinyl or quinazolinyl.
  • Embodiment 23 provides a compound of any of the preceding embodiments, wherein the C ring is pyrazolyl, imidazolyl, or triazolyl.
  • Embodiment 24 provides a compound of any of the preceding embodiments, wherein the C ring is a single, non-fused ring.
  • Embodiment 25 provides a compound of any of the preceding embodiments, wherein the C ring is a fusion of two rings.
  • Embodiment 26 provides a compound of any of the preceding embodiments, wherein the C ring is phenyl.
  • Embodiment 27 provides a compound of any of the preceding embodiments, wherein the C ring is a heterocyclyl ring containing at least one N atom.
  • Embodiment 28 provides a compound of any of the preceding embodiments, wherein the C ring is piperidinyl, piperazinyl, or morpholinyl.
  • Embodiment 29 provides a compound of any of the preceding embodiments, wherein R 1 is independently amino, C 1 -C 4 alkyl, hydroxy or halogen.
  • Embodiment 30 provides a compound of any of the preceding embodiments, wherein R 1 is independently amino or substituted C1-C4 alkyl.
  • Embodiment 31 provides a compound of any of the preceding embodiments, wherein R 1 is independently amino or unsubstituted C 1 -C 4 alkyl.
  • Embodiment 32 provides a compound of any of the preceding embodiments, wherein R 1 is amino.
  • Embodiment 33 provides a compound of any of the preceding embodiments, wherein R 1 is unsubstituted C 1 -C 4 alkyl.
  • Embodiment 34 provides a compound of any of the preceding embodiments, wherein R 2 is independently amino, C 1 -C 4 alkyl, halogen or trifluoromethyl.
  • Embodiment 35 provides a compound of any of the preceding embodiments, wherein R 2 is amino.
  • Embodiment 36 provides a compound of any of the preceding embodiments, wherein R 2 is unsubstituted C1-C4 alkyl.
  • Embodiment 37 provides a compound of any of the preceding embodiments, wherein R 2 is substituted C1-C4 alkyl.
  • Embodiment 38 provides a compound of any of the preceding embodiments, wherein R 2 is trifluoromethyl.
  • Embodiment 39 provides a compound of any of the preceding embodiments, wherein R 3 is independently C1-C4 alkyl, C1-C4 alkoxy, hydroxy, aryl, or benzyl.
  • Embodiment 40 provides a compound of any of the preceding embodiments, wherein R 3 is substituted C1-C4 alkyl.
  • Embodiment 41 provides a compound of any of the preceding embodiments, wherein R 3 is unsubstituted C1-C4 alkyl.
  • Embodiment 42 provides a compound of any of the preceding embodiments, wherein R 3 is independently CH 3 , CH 3 CHCH 3 , CH 3 CH(CH 2 )CH 3 or
  • Embodiment 43 provides a compound of any of the preceding embodiments, wherein linkage 1 is methylene or acetylene.
  • Embodiment 44 provides a compound of any of the preceding embodiments, wherein linkage 2 is
  • Embodiment 45 provides a compound of any of the preceding embodiments, wherein linkage 2 is [00275]
  • Embodiment 46 provides a compound of any of the preceding embodiments, wherein linkage 2 is alkylamido, alkenylamido, amidoalkyl, or amidoalkenyl
  • Embodiment 47 provides a compound of any of the preceding embodiments, wherein linkage 2 is alkenylamido or amidoalkenyl.
  • Embodiment 48 provides a compound of any of the preceding embodiments, wherein the B 1 ring is a heteroaromatic.
  • Embodiment 49 provides a compound of any of the preceding embodiments, wherein the B 1 ring is indazole, imadazopyridine, imadazopyrazine, imadazopyridazine, pyrrolopyridine, hexahydrothienopyrimidine, imidazole, pyrazole, pyrazine, pyridine, pyrimidine, phenylpyrimidinamine, quinolinyl, isoquinolinyl, tetrahydroquinolinyl or quinazolinyl.
  • Embodiment 50 provides a compound of any of the preceding embodiments, wherein the B 1 ring is pyrazolyl, imidazolyl, or triazolyl.
  • Embodiment 51 provides a compound of any of the preceding embodiments, wherein the B 1 ring is a single, non-fused ring.
  • Embodiment 52 provides a compound of any of the preceding embodiments, wherein the B 1 ring is a fusion of two rings.
  • Embodiment 53 provides a compound of any of the preceding embodiments, wherein the B 1 ring is phenyl.
  • Embodiment 54 provides a compound of any of the preceding embodiments, wherein the B 2 ring is pyridinyl.
  • Embodiment 55 provides a compound of any of the preceding embodiments, wherein the B 2 ring is napthyl.
  • Embodiment 56 provides a compound of any of the preceding embodiments, wherein the B 2 ring is bicyclic heterocyclyl.
  • Embodiment 57 provides a compound of any of the preceding embodiments, wherein the B 2 ring is bicyclic benzimidazole.
  • Embodiment 58 provides a compound of any of the preceding embodiments, wherein the B 2 ring is phenyl.
  • Embodiment 59 provides a compound of any of the preceding embodiments, wherein the D ring is heteroaromatic.
  • Embodiment 60 provides a compound of any of the preceding embodiments, wherein the C ring is indazole, imadazopyridine, imadazopyrazine, imadazopyridazine, pyrrolopyridine, hexahydrothienopyrimidine, imidazole, pyrazole, pyrazine, pyridine, pyrimidine, phenylpyrimidinamine, quinolinyl, isoquinolinyl, tetrahydroquinolinyl or quinazolinyl.
  • Embodiment 61 provides a compound of any of the preceding embodiments, wherein the C ring is pyrazolyl, imidazolyl, or triazolyl.
  • Embodiment 62 provides a compound of any of the preceding embodiments, wherein the C ring is a single, non-fused ring.
  • Embodiment 63 provides a compound of any of the preceding embodiments, wherein the C ring is a fusion of two rings.
  • Embodiment 64 provides a compound of any of the preceding embodiments, wherein the C ring is phenyl.
  • Embodiment 65 provides a compound of any of the preceding embodiments, wherein the C ring is a heterocyclyl ring containing at least one N atom.
  • Embodiment 66 provides a compound of any of the preceding embodiments, wherein the C ring is piperidinyl, piperazinyl, or morpholinyl.
  • Embodiment 67 provides a compound of any of the preceding embodiments, wherein R 4 is independently amino, C1-C4 alkyl, hydroxy or halogen.
  • Embodiment 68 provides a compound of any of the preceding embodiments, wherein R 4 is independently amino or substituted C1-C4 alkyl.
  • Embodiment 69 provides a compound of any of the preceding embodiments, wherein R 4 is independently amino or unsubstituted C1-C4 alkyl.
  • Embodiment 70 provides a compound of any of the preceding embodiments, wherein R 4 is amino.
  • Embodiment 71 provides a compound of any of the preceding embodiments, wherein R 4 is unsubstituted C 1 -C 4 alkyl.
  • Embodiment 72 provides a compound of any of the preceding embodiments, wherein R 5 is independently amino, C1-C4 alkyl, halogen or trifluoromethyl.
  • Embodiment 73 provides a compound of any of the preceding embodiments, wherein R 5 is independently amino, C1-C4 alkyl, or trifluoromethyl.
  • Embodiment 74 provides a compound of any of the preceding embodiments, wherein R 5 is independently amino or C 1 -C 4 alkyl, .
  • Embodiment 75 provides a compound of any of the preceding embodiments, wherein R 5 is amino.
  • Embodiment 76 provides a compound of any of the preceding embodiments, wherein R 5 is unsubstituted C1-C4 alkyl.
  • Embodiment 77 provides a compound of any of the preceding embodiments, wherein R 5 is substituted C 1 -C 4 alkyl.
  • Embodiment 78 provides a compound of any of the preceding embodiments, wherein R 5 is trifluoromethyl.
  • Embodiment 79 provides a compound of any of the preceding embodiments, wherein R 3 is independently C1-C4 alkyl, C1-C4 alkoxy, hydroxy, aryl, or benzyl.
  • Embodiment 80 provides a compound of any of the preceding embodiments, wherein R 3 is substituted C1-C4 alkyl.
  • Embodiment 81 provides a compound of any of the preceding embodiments, wherein R 3 is unsubstituted C 1 -C 4 alkyl.
  • Embodiment 82 provides a compound of any of the preceding embodiments, wherein R 3 is independently CH3, CH3CHCH3, CH3CH(CH2)CH3 or CH 3 CH 2 CH 3 OH.
  • Embodiment 83 provides a compound of any of the preceding embodiments, wherein linkage A is a single bond.
  • Embodiment 84 provides a compound of any of the preceding embodiments, wherein linkage A is methylene or acetylene.
  • Embodiment 85 provides a compound of any of the preceding embodiments, wherein linkage B is
  • Embodiment 86 provides a compound of any of the preceding embodiments, wherein linkage B is [00317]
  • Embodiment 87 provides a compound of any of the preceding embodiments, wherein linkage B is alkylamido, alkenylamido, amidoalkyl, or amidoalkenyl
  • Embodiment 88 provides a compound of any of the preceding embodiments, wherein linkage B is alkenylamido or amidoalkenyl.
  • Embodiment 89 provides a compound of any of the preceding embodiments, wherein linkage C is methylene.
  • Embodiment 90 provides a compound of any of the preceding embodiments, wherein x is 0.
  • Embodiment 91 provides a compound of any of the preceding embodiments, wherein x is 1.
  • Embodiment 92 provides a compound of any of the preceding embodiments, wherein x is 2.
  • Embodiment 93 provides a compound of any of the preceding embodiments, wherein y is 0.
  • Embodiment 94 provides a compound of any of the preceding embodiments, wherein y is 1.
  • Embodiment 95 provides a compound of any of the preceding embodiments, wherein z is 0.
  • Embodiment 96 provides a compound of any of the preceding embodiments, wherein z is 1.
  • Embodiment 97 provides a compound of any of the preceding embodiments, wherein z is 2.
  • Embodiment 98 provides a compound of any of the preceding embodiments, wherein v is 0.
  • Embodiment 99 provides a compound of any of the preceding embodiments, wherein v is 1.
  • Embodiment 100 provides a compound of any of the preceding embodiments, wherein v is 2.
  • Embodiment 101 provides a compound of any of the preceding embodiments, wherein w is 0.
  • Embodiment 102 provides a compound of any of the preceding embodiments, wherein w is 1.
  • Embodiment 103 provides a compound of any of the preceding embodiments, wherein w is 2.
  • Embodiment 104 provides a compound of any of the preceding embodiments, for use in treating cancer.
  • Embodiment 105 provides a compound of any of the preceding embodiments, for treating cancer.
  • Embodiment 106 provides a composition comprising a carrier and a compound of any one of claims 1-9.
  • Embodiment 107 provides a composition of the preceding embodiment, further comprising vitamin E, an antioxidant, a hydralazine, or any combination thereof.
  • Embodiment 108 provides a method for treating or reducing cancer in a subject in need thereof, comprising administering to the subject a compound of Embodiments 1-106.
  • Embodiment 109 provides a method for clearing cancer cells in a subject in need thereof, comprising administering to the subject a compound of Embodiments 1-106.
  • a method of inhibiting IRE ⁇ 1 comprising contacting IRE ⁇ 1 with a compound of Embodiments 1-106 or a composition of Embodiments 106 and 107.
  • Embodiment 110 provides a method of Embodiment 109, wherein the composition further comprises a pharmaceutically acceptable carrier, and at least one pharmaceutically acceptable excipient.
  • Embodiment 111 provides a method of Embodiments 109-110, wherein the composition further comprises a pharmaceutically acceptable carrier, and at least one pharmaceutically acceptable excipient.
  • Embodiment 112 provides a method of Embodiments 109-111, further comprising administering the composition to a mammal in need thereof.
  • Embodiment 113 provides a method of Embodiments 109-112, wherein the composition is suitable for oral, nasal, pulmonary, buccal, subdermal, intradermal, transdermal or parenteral, e.g., rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular, intranasal, ophthalmic solution or topical administration.
  • Embodiment 114 provides a method of Embodiments 109-113, further comprising treating a condition selected from the group consisting of neurodegenerative diseases, inflammation, metabolic disorders, liver dysfunction, brain ischemia, heart ischemia, autoimmune diseases, and cancer.
  • Embodiment 115 provides a method of Embodiments 109-114, wherein the cancer is ovarian cancer or triple negative breast cancer.
  • Embodiment 116 provides a method of Embodiments 109-115, wherein the composition blocks myeloid cell immunosuppression mediated by tumor-associated factors.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des inhibiteurs IRE1-α, des compositions contenant ces inhibiteurs, et des procédés de traitement de cancer comprenant l'administration de tels composés. Des composés donnés à titre d'exemples sont présentés dans toute l'application.
PCT/US2018/020763 2017-03-02 2018-03-02 Inhibiteurs ire1-alpha à petites molécules WO2018161033A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762466210P 2017-03-02 2017-03-02
US62/466,210 2017-03-02

Publications (1)

Publication Number Publication Date
WO2018161033A1 true WO2018161033A1 (fr) 2018-09-07

Family

ID=61683938

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/020763 WO2018161033A1 (fr) 2017-03-02 2018-03-02 Inhibiteurs ire1-alpha à petites molécules

Country Status (1)

Country Link
WO (1) WO2018161033A1 (fr)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10392367B2 (en) 2017-06-01 2019-08-27 Quentis Therapeutics, Inc. IRE1 small molecule inhibitors
US10647661B2 (en) 2017-07-11 2020-05-12 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US10730874B2 (en) 2018-03-13 2020-08-04 Shire Human Genetic Therapies, Inc. Inhibitors of plasma kallikrein and uses thereof
US10766884B2 (en) 2018-04-26 2020-09-08 Pfizer Inc. Cyclin dependent kinase inhibitors
US10894797B2 (en) 2018-09-18 2021-01-19 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors
US10988461B2 (en) 2016-03-03 2021-04-27 Cornell University Small molecule IRE1-α inhibitors
US11008325B2 (en) 2016-11-14 2021-05-18 Virginia Commonwealth University Inhibitors of cancer invasion, attachment, and/or metastasis
US11021466B2 (en) 2017-06-01 2021-06-01 Cornell University IRE1 small molecule inhibitors
CN113795254A (zh) * 2019-02-27 2021-12-14 奥普提卡拉公司 用于ire1抑制的吡唑并吡啶化合物
US11370803B2 (en) 2019-09-18 2022-06-28 Takeda Pharmaceutical Company Limited Heteroaryl plasma kallikrein inhibitors
US11787796B2 (en) 2019-09-18 2023-10-17 Takeda Pharmaceutical Company Limited Plasma Kallikrein inhibitors and uses thereof
US11827627B2 (en) 2021-06-04 2023-11-28 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
US11834441B2 (en) 2019-12-06 2023-12-05 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
US11858924B2 (en) 2020-12-17 2024-01-02 Astrazeneca N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides
US11873298B2 (en) 2017-10-24 2024-01-16 Janssen Pharmaceutica Nv Compounds and uses thereof
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005121147A1 (fr) * 2004-06-03 2005-12-22 Bayer Pharmaceuticals Corporation Derives de pyrrozolotriazine utiles pour le traitement des troubles et maladies hyperproliferatifs associes a l'angiogenese
WO2006071940A2 (fr) * 2004-12-23 2006-07-06 Deciphera Pharmaceuticals, Llc Modulateurs d'enzymes et traitements
EP1867648A1 (fr) * 2006-06-13 2007-12-19 Bayer Schering Pharma Aktiengesellschaft Pyrazolopyridines substitués, leur préparation et leur utilisation médicale
WO2008054702A1 (fr) * 2006-10-31 2008-05-08 Schering Corporation Dérivés d'anilinopipérazine et leurs méthodes d'utilisation
WO2009065096A1 (fr) * 2007-11-16 2009-05-22 University Of Medicine And Dentistry Of New Jersey Inhibiteurs de parasite à petites molécules fondés sur un mécanisme
EP2070929A1 (fr) * 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Composés d'alkynylaryle et sels correspondants, compositions pharmaceutiques contenant ceux-ci, procédés de préparation de ceux-ci et usage de ceux-ci
EP2426135A1 (fr) * 2009-04-27 2012-03-07 Shionogi&Co., Ltd. Dérivé d'urée présentant une activité inhibitrice de la pi3k
WO2014072220A1 (fr) * 2012-11-07 2014-05-15 Nerviano Medical Sciences S.R.L. Pyrimidinyl et pyridinyl-pyrrolopyridinones substitués, procédé pour leur préparation et leur utilisation en tant qu'inhibiteurs de kinases
EP2896620A1 (fr) * 2012-09-17 2015-07-22 Nanjing Sanhome Pharmaceutical Co., Ltd. Composé cyclique hétéroaromatique alcynylique et son application
WO2015108490A2 (fr) * 2014-01-17 2015-07-23 Agency For Science, Technology And Research Dérivés hétéroarylalcyne et leurs utilisations
EP2927232A1 (fr) * 2012-11-28 2015-10-07 Nanjing Sanhome Pharmaceutical Co., Ltd. Composé de type hétéroarylalcyne et ses applications
WO2017152117A1 (fr) * 2016-03-03 2017-09-08 Cornell University Inhibiteurs ire1-alpha à petites molécules
WO2017152874A1 (fr) * 2016-03-11 2017-09-14 恩瑞生物医药科技（上海）有限公司 Composé d'urée, son procédé de préparation et son utilisation médicale

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005121147A1 (fr) * 2004-06-03 2005-12-22 Bayer Pharmaceuticals Corporation Derives de pyrrozolotriazine utiles pour le traitement des troubles et maladies hyperproliferatifs associes a l'angiogenese
WO2006071940A2 (fr) * 2004-12-23 2006-07-06 Deciphera Pharmaceuticals, Llc Modulateurs d'enzymes et traitements
EP1867648A1 (fr) * 2006-06-13 2007-12-19 Bayer Schering Pharma Aktiengesellschaft Pyrazolopyridines substitués, leur préparation et leur utilisation médicale
WO2008054702A1 (fr) * 2006-10-31 2008-05-08 Schering Corporation Dérivés d'anilinopipérazine et leurs méthodes d'utilisation
WO2009065096A1 (fr) * 2007-11-16 2009-05-22 University Of Medicine And Dentistry Of New Jersey Inhibiteurs de parasite à petites molécules fondés sur un mécanisme
EP2070929A1 (fr) * 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Composés d'alkynylaryle et sels correspondants, compositions pharmaceutiques contenant ceux-ci, procédés de préparation de ceux-ci et usage de ceux-ci
EP2426135A1 (fr) * 2009-04-27 2012-03-07 Shionogi&Co., Ltd. Dérivé d'urée présentant une activité inhibitrice de la pi3k
EP2896620A1 (fr) * 2012-09-17 2015-07-22 Nanjing Sanhome Pharmaceutical Co., Ltd. Composé cyclique hétéroaromatique alcynylique et son application
WO2014072220A1 (fr) * 2012-11-07 2014-05-15 Nerviano Medical Sciences S.R.L. Pyrimidinyl et pyridinyl-pyrrolopyridinones substitués, procédé pour leur préparation et leur utilisation en tant qu'inhibiteurs de kinases
EP2927232A1 (fr) * 2012-11-28 2015-10-07 Nanjing Sanhome Pharmaceutical Co., Ltd. Composé de type hétéroarylalcyne et ses applications
WO2015108490A2 (fr) * 2014-01-17 2015-07-23 Agency For Science, Technology And Research Dérivés hétéroarylalcyne et leurs utilisations
WO2017152117A1 (fr) * 2016-03-03 2017-09-08 Cornell University Inhibiteurs ire1-alpha à petites molécules
WO2017152126A1 (fr) * 2016-03-03 2017-09-08 Cornell University Inhibiteurs ire1-alpha à petites molécules
WO2017152874A1 (fr) * 2016-03-11 2017-09-14 恩瑞生物医药科技（上海）有限公司 Composé d'urée, son procédé de préparation et son utilisation médicale

Non-Patent Citations (36)

* Cited by examiner, † Cited by third party
Title
"Design of Prodrugs", 1985, ELSEVIER
"Remington: The Science and Practice of Pharmacy", 1995
ALI ET AL., THE EMBO J, vol. 30, 2011, pages 894 - 905
ALI M M; BAGRATUNI T; DAVENPORT E L; NOWAK P R; SILVA-SANTISTEBAN M C; HARDCASTLE A ET AL.: "Structure of the Ire1 autophosphorylation complex and implications for the unfolded protein response", THE EMBO JOURNAL, vol. 30, 2011, pages 894 - 905
BIMBISAR DESAI ET AL: "Rapid Discovery of a Novel Series of Abl Kinase Inhibitors by Application of an Integrated Microfluidic Synthesis and Screening Platform", JOURNAL OF MEDICINAL CHEMISTRY, vol. 56, no. 7, 11 April 2013 (2013-04-11), pages 3033 - 3047, XP055253098, ISSN: 0022-2623, DOI: 10.1021/jm400099d *
BUCKLEY G M ET AL: "IRAK-4 inhibitors. Part 1: A series of amides", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 18, no. 11, 1 June 2008 (2008-06-01), pages 3211 - 3214, XP022711199, ISSN: 0960-894X, [retrieved on 20080426], DOI: 10.1016/J.BMCL.2008.04.058 *
CONCHA ET AL., MOLECULAR PHARMACOL, vol. 88, 2015, pages 1011 - 2
CONCHA N O; SMALLWOOD A; BONNETTE W; TOTORITIS R; ZHANG G; FEDEROWICZ K ET AL.: "Long-Range inhibitor-Induced Conformational Regulation of Human IRE1 alpha Endoribonuclease Activity", MOLECULAR PHARMACOLOGY, vol. 88, 2015, pages 1011 - 23
CONCHA, N. O. ET AL.: "Long-Range Inhibitor-Induced Conformational Regulation of Human IRE1 alpha Endoribonuclease Activity", MOL PHARMACOL, vol. 88, no. 6, 2015, pages 1011 - 23
CROSS, B. C. ET AL.: "The molecular basis for selective inhibition of unconventional mRNA splicing by an /PE1 -binding small molecule", . PROC NATI ACAD SCI USA, vol. 109, no. 15, 2012, pages E869 - 78
CUBILLOS-RUIZ ET AL., CELL, vol. 161, no. 7, 2015, pages 1527 - 38
CUBILLOS-RUIZ, J. R. ET AL.: "ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis", CELL, vol. 161, no. 7, 2015, pages 1527 - 38, XP029211961, DOI: doi:10.1016/j.cell.2015.05.025
DESAI B; DIXON K; FARRANT E; FENG Q; GIBSON K R; VAN HOORN W P ET AL.: "Rapid discovery of a novel series of Abl kinase inhibitors by application of an integrated microfluidic synthesis and screening platform", JOURNAL OF MEDICINAL CHEMISTRY, vol. 56, 2013, pages 3033 - 47, XP055253098, DOI: doi:10.1021/jm400099d
DESAI, B. ET AL.: "Rapid discovery of a novel series of Abl kinase inhibitors by application of an integrated microfluidic synthesis and screening platform", J MED CHEM, vol. 56, no. 7, 2013, pages 3033 - 47, XP055253098, DOI: doi:10.1021/jm400099d
DYMEK W ET AL: "Pyrazole derivatives. II", ACTA POLONIAE PHARMACEUTICA - DRUG RESEARCH, POLISH PHARMACEUTICAL SOCIETY, WARZSAW, PL, vol. 22, no. 3, 1 January 1965 (1965-01-01), pages 209 - 217, XP009505336, ISSN: 0001-6837 *
DYMEK W ET AL: "Studies on Pyrazole derivatives. I", ACTA POLONIAE PHARMACEUTICA - DRUG RESEARCH, POLISH PHARMACEUTICAL SOCIETY, WARZSAW, PL, vol. 21, no. 2, 1 January 1964 (1964-01-01), pages 211 - 216, XP009505330, ISSN: 0001-6837 *
HANESSIAN, DESIGN AND STRATEGY IN ORGANIC SYNTHESIS, 2013
HARRINGTON ET AL., ACS MED CHEM LETTERS, vol. 6, 2015, pages 68 - 72
HARRINGTON P E; BISWAS K; MALWITZ D; TASKER A S; MOHR C; ANDREWS K L ET AL.: "Unfolded Protein Response in Cancer: IRE1 alpha Inhibition by Selective Kinase Ligands Does Not impair Tumor Cell Viability", ACS MEDICINAL CHEMISTRY LETTERS, vol. 6, 2015, pages 68 - 72
HARRINGTON, P. E. ET AL.: "Unfolded Protein Response in Cancer: IRE1 alpha Inhibition by Selective Kinase Ligands Does Not Impair Tumor Cell Viability", ACS MED. CHEM LETT, vol. 6, no. 1, 2015, pages 68 - 72
HO, FIESERS' REAGENTS FOR ORGANIC SYNTHESIS, vol. 1- 27, 2013
LIKUN WANG ET AL: "Divergent allosteric control of the IRE1 alpha endoribonuclease using kinase inhibitors", NATURE CHEMICAL BIOLOGY, NATURE PUBLISHING GROUP, BASINGSTOKE, vol. 8, no. 12, 1 December 2012 (2012-12-01), pages 982 - 989, XP002761451, ISSN: 1552-4450, [retrieved on 20121021], DOI: 10.1038/NCHEMBIO.1094 *
LIT ET AL.: "Salt Selection for Basic Drugs", INT J. PHARM., vol. 33, 1986, pages 201 - 217
MENDEZ, A. S. ET AL.: "Endoplasmic reticulum stress-independent activation of unfolded protein response kinases by a small molecule ATP-mimic", ELITE, 2015, pages 4
MIMURA, N. ET AL.: "Blockade of XBP1 splicing by inhibition of IRE1 alpha is a promising therapeutic option in multiple myeloma", BLOOD, vol. 119, no. 24, 2012, pages 5772 - 81, XP055152535, DOI: doi:10.1182/blood-2011-07-366633
PAPANDREOU, I. ET AL.: "Identification of an Irelalpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma", BLOOD, vol. 117, no. 4, 2011, pages 1311 - 4
SANCHES ET AL., NATURE COMMUNICATIONS, vol. 5, 2014, pages 4202
SANCHES M; DUFFY N M; TALUKDAR M; THEVAKUMARAN N; CHIOVITTI D; CANNY M D ET AL.: "Structure and mechanism of action of the hydroxy-aryl-aldehyde class of IRE1 endoribonuclease inhibitors", NATURE COMMUNICATIONS, vol. 5, 2014, pages 4202
SMITH, MARCH'S ADVANCED ORGANIC CHEMISTRY: REACTIONS, MECHANISMS, AND STRUCTURE, 2013
TANG, C. H. ET AL.: "Inhibition of ER stress-associated IRE-1/XBP-1 pathway reduces leukemic cell survival", J CLIN INVEST, vol. 124, no. 6, 2014, pages 2585 - 98, XP055152530, DOI: doi:10.1172/JCI73448
VOLKMANN, K. ET AL.: "Potent and selective inhibitors of the inositol-requiring enzyme 1 endoribonuclease", J BIOL CHEM, vol. 286, no. 14, 2011, pages 12743 - 55, XP055166969, DOI: doi:10.1074/jbc.M110.199737
WANG ET AL., NATURE CHEM BIOL, vol. 8, 2012, pages 982 - 9
WANG L; PERERA B G; HARI S B; BHHATARAI B; BACKES B J; SEELIGER M A ET AL.: "Divergent allosteric control of the IRE1 alpha endoribonuclease using kinase inhibitors", NATURE CHEMICAL BIOLOGY, vol. 8, 2012, pages 982 - 9, XP002761451, DOI: doi:10.1038/nchembio.1094
WANG, L. ET AL.: "Divergent allosteric control of the IRE1 alpha endoribonuclease using kinase inhibitors", NAT CHEM BIOL, vol. 8, no. 12, 2012, pages 982 - 9, XP002761451, DOI: doi:10.1038/nchembio.1094
WUTS, GREENE'S PROTECTIVE GROUPS IN ORGANIC SYNTHESIS, 2006
YU H ET AL: "1,4-Dihydropyrazolo[4,3-d]imidazole phenyl derivatives: A novel type II Raf kinase inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 20, no. 12, 15 June 2010 (2010-06-15), pages 3805 - 3808, XP027351258, ISSN: 0960-894X, [retrieved on 20100615] *

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10988461B2 (en) 2016-03-03 2021-04-27 Cornell University Small molecule IRE1-α inhibitors
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
US11891399B2 (en) 2016-11-14 2024-02-06 Virginia Commonwealth University Inhibitors of cancer invasion, attachment, and/or metastasis
US11008325B2 (en) 2016-11-14 2021-05-18 Virginia Commonwealth University Inhibitors of cancer invasion, attachment, and/or metastasis
US10392367B2 (en) 2017-06-01 2019-08-27 Quentis Therapeutics, Inc. IRE1 small molecule inhibitors
US11021466B2 (en) 2017-06-01 2021-06-01 Cornell University IRE1 small molecule inhibitors
US11649224B2 (en) 2017-06-01 2023-05-16 Cornell University IRE1 small molecule inhibitors
US10647661B2 (en) 2017-07-11 2020-05-12 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US11603351B2 (en) 2017-07-11 2023-03-14 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US11873298B2 (en) 2017-10-24 2024-01-16 Janssen Pharmaceutica Nv Compounds and uses thereof
US10730874B2 (en) 2018-03-13 2020-08-04 Shire Human Genetic Therapies, Inc. Inhibitors of plasma kallikrein and uses thereof
US11352356B2 (en) 2018-03-13 2022-06-07 Takeda Pharmaceutical Company Limited Inhibitors of plasma kallikrein and uses thereof
US11220494B2 (en) 2018-04-26 2022-01-11 Pfizer Inc. Cyclin dependent kinase inhibitors
US10766884B2 (en) 2018-04-26 2020-09-08 Pfizer Inc. Cyclin dependent kinase inhibitors
US11459340B2 (en) 2018-09-18 2022-10-04 Nikang Therapeutics, Inc. Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors
US11518772B2 (en) 2018-09-18 2022-12-06 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors
US11034705B2 (en) 2018-09-18 2021-06-15 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors
US10894797B2 (en) 2018-09-18 2021-01-19 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors
EP3930718A4 (fr) * 2019-02-27 2022-10-05 Optikira LLC Composés de pyrazolopyridine pour l'inhibition d'ire1
CN113795254A (zh) * 2019-02-27 2021-12-14 奥普提卡拉公司 用于ire1抑制的吡唑并吡啶化合物
US11370803B2 (en) 2019-09-18 2022-06-28 Takeda Pharmaceutical Company Limited Heteroaryl plasma kallikrein inhibitors
US11787796B2 (en) 2019-09-18 2023-10-17 Takeda Pharmaceutical Company Limited Plasma Kallikrein inhibitors and uses thereof
US11834441B2 (en) 2019-12-06 2023-12-05 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
US11919887B2 (en) 2019-12-06 2024-03-05 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
US11858924B2 (en) 2020-12-17 2024-01-02 Astrazeneca N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides
US11827627B2 (en) 2021-06-04 2023-11-28 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels

Similar Documents

Publication Publication Date Title
US20210238167A1 (en) Small molecule ire1-alpha inhibitors
WO2018161033A1 (fr) Inhibiteurs ire1-alpha à petites molécules
US10544136B2 (en) Modulators of sphingosine phosphate receptors
ES2758841T3 (es) Moduladores heterocíclicos selectivos del receptor de la esfingosina-1-fosfato
US8957093B2 (en) N-biphenylmethylindole modulators of PPARG
US8507538B2 (en) Selective heterocyclic sphingosine 1 phosphate receptor modulators
WO2009017954A1 (fr) Inhibiteurs de kinase jak2
CN106176721B (zh) 有机硒化合物的癌症预防和治疗用途
CN112441957A (zh) 用于预防和治疗癌症的有机硒化合物
US20230399303A1 (en) Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same
WO2023064458A1 (fr) Inhibiteurs sélectifs de jak2 et procédés d'utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18711777

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18711777

Country of ref document: EP

Kind code of ref document: A1